[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 187
1. Di Matteo FM, De Stefano M, Vanni B, Palermo S, Biancafarina A, Giusti D, Savino G, Di Marco C, Casalvieri L, De Antoni E: [Retroperitoneal giant mixed sarcoma. Case report]. G Chir; 2008 May;29(5):238-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient underwent surgery for excision of a giant retroperitoneal mass.
  • Histology showed a mixed liposarcoma and angiosarcoma with high grade of malignancy and positivity for vimentin, factor VIII, CD34, CD31 and negativity for S-100, CD68, AMS, AML.
  • The prognosis of these tumours is closely related to local recurrence, histological type, size and radical surgery.
  • Radiation therapy and chemotherapy do not seem to have a strong influence on the prognosis.
  • An aggressive surgical approach is the first choice for the treatment of such tumors.
  • [MeSH-major] Hemangiosarcoma / surgery. Liposarcoma / surgery. Neoplasms, Multiple Primary / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507961.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


2. Chand M, Thomas RJ, Dabbas N, Bateman AC, Royle GT: Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report. World J Oncol; 2010 Jun;1(3):135-137
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft Tissue Metastases as the First Clinical Manifestation of Squamous Cell Carcinoma of the Esophagus: Case Report.
  • Soft tissue metastases are an uncommon presenting feature for primary solid tumours.
  • This case highlights a rare presentation in which a soft tissue mass is the first clinical manifestation of a widespread disseminated malignancy of the esophagus.
  • A 73-year-old woman presented with a soft swelling in the left upper quadrant of the abdomen arising from the anterior abdominal wall, suspicious of liposarcoma.
  • Immunohistochemistry suggested the most likely diagnosis was that of metastatic carcinoma with a number of potential primary sites.
  • Computed tomography scanning showed widespread metastatic disease, including lung, liver, kidney, omentum, subcutaneous and intramuscular lesions.
  • The distal esophagus was noted to be circumferentially thickened.
  • The patient remains well awaiting esophageal stenting and palliative chemotherapy.
  • In conclusion, it is important to be able to distinguish the origin of a soft-tissue swelling as the management will depend significantly on the histological type.
  • Soft-tissue metastases are rarely encountered as a presenting sign of an occult cancer.
  • Primary cancers that most commonly metastasise to soft tissues include those arising within the lung, colon and kidney.
  • The most frequent histological diagnosis is adenocarcinoma.
  • This case demonstrates the utility of biopsy in the investigation of soft tissue masses when the clinical presentation is unusual.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Plast Surg. 1993 Oct;31(4):377-8 [8239441.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • [Cites] Br J Surg. 1970 Jul;57(7):529-30 [5427475.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):193-203 [18040999.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3780-3 [17704428.001]
  • [Cites] Skeletal Radiol. 2000 May;29(5):270-4 [10883446.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):508-11 [17081724.001]
  • [Cites] Ann Thorac Surg. 1996 May;61(5):1525-6 [8633975.001]
  • (PMID = 29147193.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Biopsy / Esophagus / Occult cancer / Soft tissue metastasis / Squamous cell carcinoma
  •  go-up   go-down


3. Bradley JC, Caplan R: Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg; 2002 Jan;68(1):52-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent resection of a well-differentiated liposarcoma arising from his retroperitoneum measuring 50 cm and weighing 11.7 kg (25.8 lb).
  • This is the second largest retroperitoneal soft-tissue sarcoma (RSTS) that has been reported.
  • Over the last 15 years 1123 patients with RSTS in 25 series have been reported with a mean tumor size of 15.7 cm.
  • Diagnosis and treatment of RSTS can be extremely challenging for a general surgeon.
  • Treatment of RSTS remains surgical.
  • Multiple trials of chemotherapy and radiation therapy show no survival benefit.
  • The only successful treatment of this tumor is complete excision; 51.4 per cent of tumors can be completely excised, and 50.2 per cent of these excisions include adjacent organs.
  • With aggressive surgical therapy survival is increased to 58.0 and 39.6 per cent.
  • [MeSH-major] Liposarcoma / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467318.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


Advertisement
4. Yura S, Terahata S, Ohga N, Yamashita T: A case of carcinosarcoma arising in the submandibular gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jun;103(6):820-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man presented with an 8-year history of a hard asymptomatic mass of the left submandibular area.
  • Total excision of the left submandibular gland with radical neck dissection was performed under a diagnosis of a submandibular tumor, probably a malignant mixed tumor.
  • The pathologic diagnosis was carcinosarcoma consisting of carcinomatous and sarcomatous elements.
  • The nonepithelial component was composed of chondrosarcoma, osteosarcoma, spindle cell sarcoma, rhabdomyosarcoma, and liposarcoma.
  • The finding suggested that in our patient, the carcinosarcoma arose from a preexisting pleomorphic adenoma.
  • In view of the expected aggressive nature of the tumor, the patient was treated with postoperative radiotherapy of 60 Gy total, in 30 daily fractions of 2 Gy, and chemotherapy.
  • He currently remains well and free of disease 24 months after treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Postoperative Care. Radiotherapy, Adjuvant

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531942.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Diagnostic investigation presented a cerebral, pulmonary, cutaneous, hepatic and pleural metastatic disease.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Rajapakse CS, Martínez A, Naoulou B, Jarzecki AA, Suárez L, Deregnaucourt C, Sinou V, Schrével J, Musi E, Ambrosini G, Schwartz GK, Sánchez-Delgado RA: Synthesis, characterization, and in vitro antimalarial and antitumor activity of new ruthenium(II) complexes of chloroquine. Inorg Chem; 2009 Feb 2;48(3):1122-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new Ru(II) chloroquine complexes [Ru(eta(6)-arene)(CQ)Cl2] (CQ = chloroquine; arene = p-cymene 1, benzene 2), [Ru(eta(6)-p-cymene)(CQ)(H2O)2][BF4]2 (3), [Ru(eta(6)-p-cymene)(CQ)(en)][PF6]2 (en = ethylenediamine) (4), and [Ru(eta(6)-p-cymene)(eta(6)-CQDP)][BF4]2 (5, CQDP = chloroquine diphosphate) have been synthesized and characterized by use of a combination of NMR and FTIR spectroscopy with DFT calculations.
  • 1, 2, 3, and 5 are active against CQ-resistant (Dd2, K1, and W2) and CQ-sensitive (FcB1, PFB, F32, and 3D7) malaria parasites (Plasmodium falciparum); importantly, the potency of these complexes against resistant parasites is consistently higher than that of the standard drug chloroquine diphosphate.
  • 1 and 5 also inhibit the growth of colon cancer cells, independently of the p53 status and of liposarcoma tumor cell lines with the latter showing increased sensitivity, especially to 1 (IC50 8 microM); this is significant because this type of tumor does not respond to currently employed chemotherapies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLOROQUINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2005 Apr 21;48(8):2814-21 [15828819.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Dec;43(12):595-6 [16372531.001]
  • [Cites] Bioorg Med Chem. 2006 May 1;14(9):3218-22 [16413786.001]
  • [Cites] Dalton Trans. 2006 Apr 28;(16):1929-33 [16609762.001]
  • [Cites] Drug Resist Updat. 2006 Aug-Oct;9(4-5):211-26 [17064951.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23):6858-68 [17154516.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6626-36 [17638873.001]
  • [Cites] Bioorg Med Chem. 2007 Oct 15;15(20):6510-6 [17693090.001]
  • [Cites] Inorg Chem. 2007 Oct 15;46(21):8950-62 [17850143.001]
  • [Cites] Dalton Trans. 2008 Jan 14;(2):183-94 [18097483.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):15-7 [18097478.001]
  • [Cites] J Clin Invest. 2008 Jan;118(1):79-88 [18097482.001]
  • [Cites] PLoS One. 2008;3(1):e1493 [18231580.001]
  • [Cites] Expert Rev Vaccines. 2008 Mar;7(2):223-40 [18324891.001]
  • [Cites] ChemMedChem. 2008 Mar;3(3):383-91 [17806092.001]
  • [Cites] Curr Opin Chem Biol. 2008 Apr;12(2):197-206 [18155674.001]
  • [Cites] Vaccine. 2008 Apr 24;26(18):2191-202 [18387719.001]
  • [Cites] J Biol Inorg Chem. 2008 Jun;13(5):703-12 [18305967.001]
  • [Cites] J Med Chem. 2001 Oct 25;44(22):3616-21 [11606126.001]
  • [Cites] Nature. 2002 Feb 7;415(6872):680-5 [11832956.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3611-6 [12655051.001]
  • [Cites] Curr Med Chem. 2003 Oct;10(19):2033-44 [12871101.001]
  • [Cites] Curr Opin Chem Biol. 2003 Aug;7(4):481-9 [12941423.001]
  • [Cites] Curr Pharm Des. 2003;9(25):2078-89 [14529417.001]
  • [Cites] Malar J. 2003 Sep 1;2:26 [14505493.001]
  • [Cites] Malar J. 2003 Sep 19;2:31 [14599295.001]
  • [Cites] Mini Rev Med Chem. 2004 Jan;4(1):23-30 [14754440.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):376-84 [15382061.001]
  • [Cites] Biochem Pharmacol. 2004 Nov 1;68(9):1729-38 [15450938.001]
  • [Cites] J Med Chem. 2004 Oct 7;47(21):5204-9 [15456263.001]
  • [Cites] Lancet. 2004 Oct 16-22;364(9443):1411-20 [15488216.001]
  • [Cites] Science. 1976 Aug 20;193(4254):673-5 [781840.001]
  • [Cites] Ann Trop Med Parasitol. 1978 Feb;72(1):87-8 [350172.001]
  • [Cites] Antimicrob Agents Chemother. 1979 Dec;16(6):710-8 [394674.001]
  • [Cites] Science. 1984 Jan 6;223(4631):58-61 [6318313.001]
  • [Cites] Mol Pharmacol. 1988 Apr;33(4):454-62 [3162758.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1243-50 [2297772.001]
  • [Cites] J Med Chem. 1993 Jul 9;36(14):2041-3 [8336342.001]
  • [Cites] J Med Chem. 1996 Mar 1;39(5):1095-99 [8676344.001]
  • [Cites] J Med Chem. 1997 Jun 6;40(12):1937-9 [9191972.001]
  • [Cites] Biochem Pharmacol. 1997 Aug 1;54(3):373-80 [9278096.001]
  • [Cites] J Med Chem. 1997 Nov 7;40(23):3715-8 [9371235.001]
  • (PMID = 19119867.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM076168-030004; United States / NIGMS NIH HHS / GM / S06 GM076168; United States / NIGMS NIH HHS / GM / 1S06 GM 076168-04; United States / NIGMS NIH HHS / GM / S06 GM076168-030004
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimalarials; 0 / Antineoplastic Agents; 0 / Ruthenium Compounds; 886U3H6UFF / Chloroquine
  • [Other-IDs] NLM/ NIHMS86722; NLM/ PMC2673146
  •  go-up   go-down


7. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • Cytogenetic analysis of his bone marrow showed multiple aberrations, including the presence of a supernumerary chromosome.
  • It represented an inverted duplication of the segments between 1q21 and 1qter with a neocentromere in band 1q31.
  • To our knowledge, this is the second reported case of NHL (both T-cell) with the presence of a neocentromere.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Stojanović M, Goldner B, Djukić S: [Unusual biological behaviour of femoral liposarcoma]. Srp Arh Celok Lek; 2007 Jul-Aug;135(7-8):468-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual biological behaviour of femoral liposarcoma].
  • INTRODUCTION: Liposarcoma of a bone is a very rare tumour of the fatty marrow, originating from lipoblasts.
  • Surgical resection-amputation, chemotherapy and radiotherapy are the therapeutic methods of choice.
  • There was a histologically proved liposarcoma of a high grade of malignancy.
  • According to the therapeutic protocol, chemotherapy and radiotherapy were applied.
  • During the period of 12 years, the patient had a relapse on the stump, metastatic dissemination in the soft tissue of small pelvis twice, once in the left scapular region and in the inguinal lymph nodes, six operations and 8-year accumulation of metastatic deposits in the lung.
  • CONCLUSION: Unusual behaviour of the liposarcoma of high grade malignancy with which the patient has been living for 12 years, could be explained by the patient's strong immunobiological system in the struggle to retain its vitality and mobility.
  • [MeSH-major] Femoral Neoplasms / pathology. Liposarcoma / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Soft Tissue Neoplasms / secondary

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929542.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


9. Bánky B, Bányász Z, Mayer A, Almási K, Szucs I: [Giant retroperitoneal liposarcoma--case report]. Magy Seb; 2005 Jun;58(3):190-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant retroperitoneal liposarcoma--case report].
  • Retroperitoneal liposarcomas are the most frequent soft tissue sarcomas and the second most frequent retroperitoneal tumours.
  • Hereby we describe the treatment of our patient where of a 15-kg giant retroperitoneal liposarcoma was successfully removed and a local recurrence two years later was operated on as well.
  • This was the 3rd largest retroperitoneal malignant tumor that was successfully removed according to the available literature of the last five decades.
  • The "gold-standard" of treatment remains surgical total excision, but the high local recurrence rate (50-60%) hopefully can be reduced by adjuvant radio- and chemotherapy.
  • Multidisciplinary treatment and long-time follow-up can provide as high as 40% 5-year survival rate.
  • We summarize the recent clinical, diagnostic and therapeutic methods of this rare condition.
  • [MeSH-major] Liposarcoma. Retroperitoneal Neoplasms
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167475.001).
  • [ISSN] 0025-0295
  • [Journal-full-title] Magyar sebészet
  • [ISO-abbreviation] Magy Seb
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


10. García Morúa A, Lozano Salinas JF, Valdés Sepúlveda F, Zapata H, Gómez Guerra LS: [Liposarcoma of the espermatic cord: our experience and review of the literature]. Actas Urol Esp; 2009 Jul-Aug;33(7):811-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the espermatic cord: our experience and review of the literature].
  • [Transliterated title] Liposarcoma del cordón espermático: nuestra experiencia y revisión de la literatura.
  • Sarcomas includes 90% of the espermatic cord malignant lessons and approximately the 3-7% are liposarcomas.
  • MATERIAL AND METHODS: We presented our experience with two cases of paratesticular liposarcomas.
  • RESULTS: Actually it has been reported near 161 cases of paratesticular liposarcoma.
  • Due to the rarely of this pathology it is difficult to know its natural history and to reach conclusions of the treatment results, which one until the moment continues being radical orchiectomy with wide local resection of the surrounding soft tissues, the value of adjuvant radiation and chemotherapy is even controversial.
  • CONCLUSIONS: Sarcomas of the espermatic cord are rare, their initial treatment is surgical, we recommended the transoperatory valuation of the surgical edges to try to diminish the recurrence frequency.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19757668.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 18
  •  go-up   go-down


11. Ohashi T, Imokawa H, Kenmochi M, Sato S: Neck metastasis of a myxoid liposarcoma of the lower extremity. Auris Nasus Larynx; 2004 Dec;31(4):443-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neck metastasis of a myxoid liposarcoma of the lower extremity.
  • We report the clinical features of two cases presenting metastatic neck tumors (in the anterior neck and submandibular regions) secondary to myxoid liposarcoma of the lower extremity.
  • Such repeated surgical procedures are thought to be a risk factor for distant metastasis resulting from hematogeneous dissemination of tumor cells, although there is considerable debate about multicentricity versus metastasis in liposarcomas.
  • Where possible, therapy for liposarcomas should initially comprise complete and wide resection of the lesions.
  • Combined therapy consisting of surgery and postoperative radiation and chemotherapy should be investigated in the future.
  • [MeSH-major] Liposarcoma, Myxoid / secondary. Muscle Neoplasms / pathology. Muscle, Skeletal / pathology. Submandibular Gland Neoplasms / secondary

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15571922.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Lee TY, Folkman J, Javaherian K: HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS One; 2010 Apr 01;5(4):e9945
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This 20 amino acids synthetic peptide prevents VEGF(165) binding to several different cell types, mouse embryonic sections and inhibits endothelial cell migration, despite its absence in VEGF(165) sequence.
  • Our in vivo anti-tumor studies show that the peptide inhibits tumor growth in both mouse Lewis-Lung Carcinoma and human Liposarcoma tumor-bearing animal models.
  • We conclude that the above HPSG binding peptide (6a-P) is a potent inhibitor of angiogenesis-dependent diseases.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Mar;114(Pt 5):853-65 [11181169.001]
  • [Cites] Semin Cell Dev Biol. 2001 Apr;12(2):127-34 [11292378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):280-91 [12417410.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Glycoconj J. 2002 May-Jun;19(4-5):363-8 [12975617.001]
  • [Cites] Development. 2003 Dec;130(25):6245-55 [14602684.001]
  • [Cites] Development. 2004 Feb;131(3):601-11 [14729575.001]
  • [Cites] EMBO Rep. 2004 Mar;5(3):262-7 [14978510.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):68-76 [1998521.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] Science. 1992 Feb 21;255(5047):989-91 [1312256.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86 [1417831.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6729-33 [7896817.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11322-6 [7744769.001]
  • [Cites] J Cell Biol. 1995 May;129(4):895-8 [7538139.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5638-46 [8621427.001]
  • [Cites] Cancer Metastasis Rev. 1996 Jun;15(2):153-8 [8842486.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7151-8 [9054410.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):709-14 [9251237.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1952-9 [9581838.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):24979-82 [9737951.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Nature. 1999 Jul 15;400(6741):281-4 [10421372.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jul;6(7):530-41 [16072037.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):24-31 [15996656.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Biol Chem. 2006 Jan 20;281(3):1731-40 [16258170.001]
  • (PMID = 20376344.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA045548; United States / NCI NIH HHS / CA / R01 CA064481; United States / NCI NIH HHS / CA / P01-CA45548; United States / NCI NIH HHS / CA / R01-CA064481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Heparan Sulfate Proteoglycans; 0 / Peptides; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2848586
  •  go-up   go-down


13. Kuhnen C, Müller KM, Steinau HU, Lehnhardt M: [Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings]. Pathologe; 2004 Nov;25(6):437-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy-induced tumor regression in adult soft tissue sarcomas-morphological findings].
  • [Transliterated title] Therapieinduzierte Tumorregression in Weichgewebssarkomen des Erwachsenenalters. Morphologische Befunde.
  • Morphological findings of 21 soft tissue sarcomas of adulthood following preoperative chemo- and/or radiotherapy including perfusion therapy and resection are presented.
  • The therapy-induced changes included a spectrum ranging from total tumor regression up to still completely vital tumor (median of all cases: 30% vital tumor tissue).
  • So-called malignant fibrous histiocytoma (MFH) revealed a good tumor response to preoperatively administered therapy (regression grades I and II).
  • Myxoid/round-cell liposarcoma exhibited regression grades of IV-V (i.e.
  • 30% up to 95% vital tumor tissue, non-responders).
  • Synovial sarcoma was characterized by regression grades III up to VI (i.e. up to 100% vital tumor tissue without any signs of regression, 83% non-responders).
  • Completely vital tumor was evident in 2 synovial sarcomas despite preoperative tumor therapy.
  • A grading of therapy-induced tumor regression in adult soft tissue sarcomas may best refer to already established grading schemes (e.g. according to the grading scheme for osteosarcomas following chemotherapy of Salzer-Kuntschik).
  • A report of sarcoma resection specimens should include the percentage of vital tumor tissue.
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Prostate. 1982;3(6):531-42 [7155986.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Pathologe. 1985 Jan;6(1):16-23 [3983083.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1587-9 [11527682.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;106 Suppl:21-4 [6577010.001]
  • [Cites] Pathologe. 1985 Jan;6(1):3-7 [3983085.001]
  • [Cites] Pathologe. 1996 Jan;17(1):35-43 [8685094.001]
  • [Cites] Pathologe. 1983 May;4(3):135-41 [6576329.001]
  • [Cites] Pathologe. 1997 Mar;18(2):131-40 [9244871.001]
  • [Cites] Ann Surg Oncol. 2000 Mar;7(2):155-9 [10761796.001]
  • [Cites] Pathologe. 2004 May;25(3):193-201 [15138700.001]
  • (PMID = 15449026.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Moureau-Zabotto L, Thomas L, Bui BN, Chevreau C, Stockle E, Martel P, Bonneviale P, Marques B, Coindre JM, Kantor G, Matsuda T, Delannes M: Management of soft tissue sarcomas (STS) in first isolated local recurrence: a retrospective study of 83 cases. Radiother Oncol; 2004 Dec;73(3):313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of soft tissue sarcomas (STS) in first isolated local recurrence: a retrospective study of 83 cases.
  • PURPOSE: To analyze the management and clinical outcome of patients treated for a first isolated local recurrence of soft tissue sarcomas (trunk or extremities) and to identify prognosis factors.
  • Histologic subtypes were mainly grade 2 (42%) or 3 (36%) histiocytofibrosarcomas (49%) and liposarcomas (20%).
  • Surgical treatment of recurrences consisted in wide excision (29 cases), marginal resection (43 cases), 5 patients requiring amputation.
  • Besides surgery, 6 patients received neo-adjuvant and 7 others adjuvant chemotherapy.
  • Twenty three patients received post-operative external beam radiotherapy (EBRT) (mean dose 55 Gy) and 26 interstitial 192Ir low dose rate brachytherapy (BCT) (mean dose 45 Gy for BCT alone, 22 Gy when associated with EBRT), 19 patients being re-irradiated.
  • Nineteen patients developed distant metastases.
  • Multivariate analysis showed trunk (P=0.0001) or inferior extremity locations (P=0.023), symptomatic (P=0.001), high grade (P=0.01), deep (P=0.01) tumors, and the occurrence of a further local failure (P=0.004) as unfavorable characteristics for overall survival.
  • CONCLUSIONS: A first isolated local recurrence of STS increases mainly the risk of a subsequent local relapse.
  • Quality of local treatment is decisive.
  • When a conservative treatment is feasible, it should combine surgical resection and radiotherapy, BCT being the best suited in previously irradiated patients.
  • Efforts have to be pursued to increase quality of the treatment of primary tumors, at best performed in centers that have expertise in this field.
  • [MeSH-major] Fibrosarcoma / pathology. Fibrosarcoma / radiotherapy. Liposarcoma / pathology. Liposarcoma / radiotherapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Sarcoma / pathology. Sarcoma / radiotherapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15588876.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


15. Powitzky R, Powitzky ES, Garcia R: Liposarcoma of the larynx. Ann Otol Rhinol Laryngol; 2007 Jun;116(6):418-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the larynx.
  • OBJECTIVES: The objective was to review the presentation, diagnosis, treatment, and prognosis of patients with laryngeal liposarcoma (LLS).
  • The outcomes of this disease are generally good when it is treated with wide surgical excision.
  • Because the histologic changes are frequently subtle, LLS can be easily mistaken for a benign tumor.
  • As a result, the diagnosis requires a high index of suspicion and diligence in examining biopsy specimens.
  • Computed tomography and magnetic resonance imaging can assist in the diagnosis and surgical approach.
  • Genetic and immunostaining analysis techniques may also prove to have valuable prognostic, diagnostic, and therapeutic implications for this disease.
  • Wide surgical excision is the mainstay of treatment.
  • The use of radiotherapy and chemotherapy in treating this cancer remains experimental, but might be considered on a case-to-case basis for palliation or to treat aggressive variants of the disease.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Liposarcoma / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672243.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Marolla A, Pardolesi A, Camplese P, Politi R, Sacco R: Giant posterior mediastinal liposarcoma invading the esophagus: a case report. Rays; 2006 Jan-Mar;31(1):17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant posterior mediastinal liposarcoma invading the esophagus: a case report.
  • Giant liposarcoma is an unusual variant of mediastinal tumors.
  • The case of a 73-year-old woman is reported.
  • She presented with a posterior mediastinal tumor invading the third middle tract of the thoracic esophagus and the adventitia of the descending aorta, close to the posterior pericardium; a neoplastic thrombus 2cm in size was located in the upper left pulmonary vein.
  • The postoperative course was uneventful and the patient received adjuvant chemotherapy.
  • She is currently alive after 8 months, disease-free.
  • The natural history, pathology, and prognosis of the disease are reviewed and management of such lesions is discussed.
  • [MeSH-major] Esophagus / pathology. Liposarcoma / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Aged. Aorta, Thoracic / pathology. Chemotherapy, Adjuvant. Female. Humans. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999370.001).
  • [ISSN] 0390-7740
  • [Journal-full-title] Rays
  • [ISO-abbreviation] Rays
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Ylagan LR, Bhalla S: Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. Acta Cytol; 2001 Jul-Aug;45(4):641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up.
  • BACKGROUND: Dedifferentiation is a histologic progression of a neoplasm from low grade to high grade histology.
  • It occurs in tumors of the retroperitoneum and in those undergoing treatment.
  • This usually occurs in the setting of radiation or chemotherapy or as a spontaneous process over a long period.
  • CASE: We report the cytologic features of a dedifferentiated liposarcoma arising in a 76-year-old man who had a history of well-differentiated liposarcoma.
  • There were multinucleated, pleomorphic giant cells with abundant cytoplasm, smaller clusters of cells with a high nuclear/cytoplasmic ratio and cells with spindled and elongated nuclear features.
  • The follow-up surgical resection specimen showed a dedifferentiated liposarcoma with strong and diffuse immunoreactivity to vimentin, desmin and CD68 in the large, pleomorphic cells; focal and weak immunoreactivity to smooth muscle actin and S-100 in these cells; and strong and focal immunoreactivity to desmin, smooth muscle actin and muscle-specific actin in the spindle cells.
  • CONCLUSION: Dedifferentiation of a well-differentiated liposarcoma should be entertained in the setting of a mass lesion in the retroperitoneum in patients with prior histories of well-differentiated liposarcoma.
  • The radiologic features of a particular neoplastic process can be very helpful in determining the nature of this process.
  • [MeSH-major] Biopsy, Needle. Liposarcoma / pathology. Pelvic Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Pelvis / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480734.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. Quek PL, Tan L, Lim PH: Liposarcoma of the spermatic cord. Int Surg; 2000 Apr-Jun;85(2):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the spermatic cord.
  • A case of spermatic cord liposarcoma is reported in a 40-year-old man.
  • The clinical presentation, pathogenesis and role of sonography in pre-operative diagnosis is reviewed.
  • The role of radical orchiectomy, retroperitoneal lymph node dissection, radiation therapy and chemotherapy in treatment of spermatic cord liposarcomas is discussed.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Orchiectomy. Spermatic Cord
  • [MeSH-minor] Adult. Biopsy. Diagnosis, Differential. Humans. Lymph Node Excision. Male. Retroperitoneal Space / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int Surg 2000 Oct-Dec;85(4):302
  • (PMID = 11071338.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] ITALY
  • [Number-of-references] 13
  •  go-up   go-down


20. Loubignac F, Bourtoul C, Chapel F: Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance. World J Surg Oncol; 2009;7:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myxoid liposarcoma: a rare soft-tissue tumor with a misleading benign appearance.
  • BACKGROUND: Lipoma is by far the most common of all benign soft-tissue tumors which far outnumber malignant tumors.
  • Soft-tissue sarcomas are malignant tumors and are usually named for the type of tissue in which they begin.
  • Liposarcoma (LPS), which arises in the fatty tissue, is rather an uncommon soft-tissue tumor.
  • Multiple histologic subtypes of liposarcoma are recognized, including myxoid liposarcoma, and correspond to tumors of very different prognosis.
  • In two-third of the cases, this tumor occurs in the muscle while often demonstrating a misleading benign appearance as observed in the majority of soft-tissue sarcomas.
  • CASE PRESENTATION: We report the case of a 50-year-old man operated on for a fat tumor of the thigh initially diagnosed as lipoma but revealing to be a myxoid liposarcoma after histopathological examination.
  • The initial incomplete tumor excision required the need for a re-excision with adjuvant chemotherapy and complementary radiotherapy.
  • CONCLUSION: When any suspicious soft-tissue tumor is diagnosed, the combined information gathered from accurate preoperative radiographic planning and X-rays or surgical biopsy is of tremendous value for establishing the most appropriate therapeutic program, highly adapted to the histopathological findings.
  • [MeSH-major] Liposarcoma, Myxoid / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Pathol. 1998 Dec;18(6):505-11 [10051921.001]
  • [Cites] Ann Pathol. 1998 Dec;18(6):473-80 [10051914.001]
  • [Cites] Ann Pathol. 1998;18(5 Suppl):59-63 [9884758.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2005 Apr;17(2):130 [15830582.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2006 Nov;92(7):637-50 [17124447.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1450-8 [8608528.001]
  • (PMID = 19386100.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2678127
  •  go-up   go-down


21. Terenziani M, D'Angelo P, Bisogno G, Boldrini R, Cecchetto G, Collini P, Conte M, De Laurentis T, Ilari I, Indolfi P, Inserra A, Piva L, Siracusa F, Spreafico F, Tamaro P, Lo Curto M: Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience. Pediatr Blood Cancer; 2010 Apr;54(4):532-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoma with a malignant somatic component in pediatric patients: the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
  • BACKGROUND: Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse.
  • PROCEDURE: The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC.
  • RESULTS: The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1).
  • Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosarcoma plus neuroectodermal sarcoma (1), malignant peripheral nerve sheath tumor (1).
  • Six patients are alive and disease-free.
  • The pediatric disease appears to be more heterogeneous in tumor site distribution and MSC histology than in adults.
  • Surgery has an essential role in localized disease, with complete resection highly desirable.
  • Chemotherapy optimized for histology should include reagents directed to the somatic malignancy, if chemosensitive.
  • Malignant GCT warrants GCT-directed chemotherapy.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Italy. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome


22. Thallinger C, Wolschek MF, Maierhofer H, Skvara H, Pehamberger H, Monia BP, Jansen B, Wacheck V, Selzer E: Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res; 2004 Jun 15;10(12 Pt 1):4185-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide.
  • PURPOSE: Little is known about the role that Mcl-1, an antiapoptotic Bcl-2 family member, plays in solid tumor biology and susceptibility to anticancer therapy.
  • EXPERIMENTAL DESIGN: SCID mice (n = 6/group) received s.c. injections of SW872 liposarcoma cells.
  • However, use of Mcl-1 antisense oligonucleotides combined with cyclophosphamide clearly enhanced tumor cell apoptosis and significantly reduced tumor weight by more than two-thirds compared with respective control treatments.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Drug Resistance, Neoplasm. Neoplasm Proteins / metabolism. Oligonucleotides, Antisense / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / metabolism. Sarcoma / drug therapy. Sarcoma / metabolism
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Cell Line, Tumor. Dose-Response Relationship, Drug. Down-Regulation. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Mice. Mice, SCID. Myeloid Cell Leukemia Sequence 1 Protein. Neoplasm Transplantation. Oligonucleotides / chemistry. Staurosporine / pharmacology. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217956.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mcl1 protein, mouse; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Neoplasm Proteins; 0 / Oligonucleotides; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; H88EPA0A3N / Staurosporine
  •  go-up   go-down


23. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • An objective response was reported in 33% of patients (53% in those with synovial sarcoma); 22% had stable disease and 45% derived 'clinical benefit' (objective responses + stable disease for >or= 6 months).
  • In multivariate analysis, age <40 years, liposarcoma, and synovial histology were found to be positive, and bone involvement to be negative, independent prognostic factors.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • Synovial sarcoma and liposarcoma subtypes have a better prognosis.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Peyrí Rey E, Urban Ramón A, Martínez Fernández M, Sanmarti Da Silva B: [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected]. Actas Urol Esp; 2003 May;27(5):383-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected].
  • [Transliterated title] Liposarcoma dediferenciado del cordón espermático: degeneración de un lipoma previo resecado.
  • Dedifferentiated liposarcoma accounts for only 10% of all spermatic cord sarcomas.
  • These are usually large-sized tumours histologically characterised for being well-differentiated liposarcomas with some high grade sarcoma areas.
  • These are useful for post-treatment follow-up.
  • This paper presents one spermatic cord, dedifferentiated liposarcoma from which lipomas from the same spermatic cord had been previously removed in three occasions.
  • Value of adjuvant radio- and chemotherapy is uncertain.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Lipoma / pathology. Liposarcoma / pathology. Spermatic Cord / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891917.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


25. Ninomiya H, Miyoshi T, Shirakusa T, Shiraishi T, Yamamoto N, Nabeshima K: Postradiation sarcoma of the chest wall: report of two cases. Surg Today; 2006;36(12):1101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We herein present two cases with this disease.
  • A 54-year-old man had undergone a lobectomy and chest wall resection for Pancoast type lung cancer 7 years previously.
  • He had undergone irradiation with a total dose of 50 Gy.
  • Computed tomography (CT) demonstrated a tumorous expansion of the right lateral thoracic wall.
  • A pathological examination confirmed a diagnosis of osteosarcoma.
  • A 60-year-old woman had undergone a resection of the lateral chest wall mass, which was diagnosed to be Hodgkin's disease in 1991.
  • Chemotherapy was given postoperatively.
  • A tumorous lesion arose again and irradiation was performed with a total dose of 110 Gy.
  • In 2003, a tumor recurred and was diagnosed to be a liposarcoma.
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Follow-Up Studies. Hodgkin Disease / radiotherapy. Humans. Lung Neoplasms / radiotherapy. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Dec 1;62(11):2330-40 [3179948.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Ann Thorac Surg. 1997 Jan;63(1):214-9 [8993268.001]
  • [Cites] Semin Oncol. 1991 Dec;18(6):603-12 [1775977.001]
  • [Cites] Mayo Clin Proc. 1981 May;56(5):294-306 [6939953.001]
  • [Cites] Arch Surg. 1992 Dec;127(12):1379-85 [1365680.001]
  • [Cites] Am J Clin Oncol. 1989 Oct;12(5):411-5 [2508462.001]
  • [Cites] Pathol Int. 2003 Jan;53(1):46-50 [12558870.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):951-61 [10571202.001]
  • [Cites] Breast J. 2002 Sep-Oct;8(5):320-2 [12199765.001]
  • [Cites] J Surg Oncol. 1985 Mar;28(3):168-71 [3838353.001]
  • (PMID = 17123140.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Blanchard DK, Reynolds CA, Grant CS, Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg; 2003 Oct;186(4):359-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to examine the presentation, treatment, and prognosis of patients presenting with these neoplasms.
  • METHODS: This was a retrospective review of patients with a primary breast sarcoma treated at Mayo Clinic, Rochester, Minnesota, between 1975 and 2001.
  • RESULTS: Of the 55 patients, 17 had breast-conserving therapy and 38 women had mastectomy.
  • The types of sarcoma included angiosarcoma (18), malignant fibrous histiocytoma (11), stromal sarcoma (8), liposarcoma (4), leiomyosarcoma (4), dermatofibrosarcoma protuberans (4), osteosarcoma (3), fibrosarcoma (2), and rhabdomyosarcoma (1).
  • Follow-up information was available for 53 patients, with a mean follow-up of 81 months.
  • Twenty-nine of 53 patients (55%) developed recurrent sarcoma, and 23 patients (43%) died of their disease.
  • Twenty-seven patients had no evidence of recurrence, and 3 patients were alive with disease at last follow-up.
  • Of 34 patients who did not receive adjuvant chemotherapy or radiation, 13 died of their disease (38%), as compared with 10 of 16 patients (63%) who did receive adjuvant therapy.
  • CONCLUSIONS: While primary nonphylloides breast sarcomas are rare tumors, their treatment and prognosis are poor.
  • Adjuvant chemotherapy and radiation did not improve survival in this report.
  • Surgical extirpation remains the only effective treatment.


27. Lehnhardt M, Daigeler A, Homann HH, Hauser J, Langer S, Steinsträsser L, Soimaru C, Puls A, Steinau HU: [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases]. Chirurg; 2009 Apr;80(4):341-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].
  • [Transliterated title] Die Bedeutung von Referenzzentren in Diagnose und Therapie von Weichgewebssarkomen der Extremitäten. Auswertung von 603 Fällen.
  • Correct histopathologic diagnosis is essential for adequate treatment of soft tissue sarcomas.
  • Due to the disorder's rarity, multitude of subgroups, sometimes varying histopathologic appearance, and occasionally inadequate biopsy specimens, diagnosis and grading are challenging.
  • The records of 603 patients with soft tissue tumors of the extremities were reviewed concerning mismatches in primary and definite diagnoses relating to entity, evaluation of primary or recurrent tumor specimens, and the diagnosing pathology institution.
  • Liposarcoma and malignant fibrous histiocytoma were the most often diagnosed subgroups at 24% and 22.6%, respectively.
  • In the eight most frequent sarcoma types, malignant peripheral nerve sheath tumors and leiomyosarcoma had the highest rates of false primary diagnosis, 78.4% and 74.2% of cases, respectively.
  • For optimal treatment of soft tissue sarcomas, we suggest obtaining expert second opinion to ensure adequate surgical therapy and precise indications for radiation and chemotherapy.
  • [MeSH-major] Cancer Care Facilities. Extremities / surgery. Hospitals, Special. Hospitals, University. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Diagnostic Errors. Female. Germany. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Liposarcoma / diagnosis. Liposarcoma / pathology. Liposarcoma / surgery. Male. Middle Aged. Neoplasm Staging. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / pathology. Nerve Sheath Neoplasms / surgery. Radiotherapy, Adjuvant. Referral and Consultation. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Cancer Treat Res. 2004;120:43-63 [15217217.001]
  • [Cites] Invest New Drugs. 2006 May;24(3):249-53 [16133789.001]
  • [Cites] Int J Hyperthermia. 2006 May;22(3):235-9 [16754344.001]
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):514-7 [7605166.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):300-6 [15946590.001]
  • [Cites] Can J Surg. 1988 Nov;31(6):404-6 [3179848.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Chirurg. 2001 May;72(5):501-13 [11383061.001]
  • [Cites] J Surg Oncol. 2008 Jan 1;97(1):40-3 [17918224.001]
  • [Cites] Chirurg. 2004 Dec;75(12):1182-90 [15309264.001]
  • [Cites] Ann Diagn Pathol. 1999 Feb;3(1):48-61 [9990113.001]
  • [Cites] Curr Top Pathol. 1995;89:123-51 [7882706.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):556-9 [11872349.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):451-62 [15509479.001]
  • [Cites] Pathol Res Pract. 1988 Nov;183(6):698-705 [2851775.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Invest New Drugs. 2003 Nov;21(4):481-6 [14586217.001]
  • [Cites] Acta Orthop Scand Suppl. 2004 Apr;75(311):77-86 [15188669.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):212-9 [10613171.001]
  • [Cites] Bull Cancer. 2001 Aug;88(8):765-73 [11578945.001]
  • [Cites] Curr Oncol Rep. 2006 Jul;8(4):305-9 [17254531.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Bone Joint Surg Am. 1996 May;78(5):656-63 [8642021.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):111-5 [11823981.001]
  • [Cites] Chirurg. 2007 Jan;78(1):62-4 [16786340.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):157-67 [11856592.001]
  • [Cites] Expert Rev Anticancer Ther. 2004 Apr;4(2):237-46 [15056054.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] Verh Dtsch Ges Pathol. 2006;90:59-72 [17867581.001]
  • [Cites] Cancer Treat Res. 1993;67:1-22 [8102867.001]
  • [Cites] Am J Clin Pathol. 2000 Sep;114(3):329-35 [10989631.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • (PMID = 18523742.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Husain EA, Prescott RJ, Haider SA, Al-Mahmoud RW, Zelger BG, Zelger B, Al-Daraji WI: Gallbladder sarcoma: a clinicopathological study of seven cases from the UK and Austria with emphasis on morphological subtypes. Dig Dis Sci; 2009 Feb;54(2):395-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to evaluate the histological features of a case series of this rare tumor and correlate these with clinical features.
  • RESULT: PGBS occurred in one male and six females with a median age of 70 (range 64-82) years.
  • Tumors ranged from 1.1 to 4 cm with a median size of 3 cm.
  • Based on morphological and immunohistochemical features of the PGBS, there were three myxofibrosarcomas (malignant fibrous histiocytoma, MFH, storiform pleomorphic), one leiomyosarcoma (LMS), one angiosarcoma (AS), and two liposarcomas (LS).
  • All patients received cholecystectomy and three received adjuvant chemotherapy.
  • Follow-up revealed that six patients died of the disease 6 weeks to 2 years after diagnosis and one died of unrelated causes.
  • A variety of sarcoma types are found with MFH being the predominant variant.

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2001 Jan;438(1):1-12 [11213830.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(1):91-102 [7123848.001]
  • [Cites] Acta Chir Belg. 2004 Feb;104(1):107-9 [15053476.001]
  • [Cites] Histopathology. 1994 Mar;24(3):269-71 [7726886.001]
  • [Cites] Am J Gastroenterol. 1986 Mar;81(3):202-4 [3513545.001]
  • [Cites] Gut. 1994 Jun;35(6):854-6 [8020820.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):571-3 [15086299.001]
  • [Cites] Rev Invest Clin. 1989 Apr-Jun;41(2):159-64 [2781178.001]
  • [Cites] Am Surg. 2001 Jul;67(7):714-7 [11450796.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1420-3 [11023105.001]
  • [Cites] Acta Oncol. 1998;37(2):212-4 [9636020.001]
  • [Cites] Cancer. 1982 Feb 15;49(4):812-8 [7055789.001]
  • [Cites] Arch Pathol Lab Med. 2002 Apr;126(4):481-3 [11900579.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1982;396(2):225-30 [6289513.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):410-4 [1617591.001]
  • [Cites] Indian J Pathol Microbiol. 1993 Jan;36(1):78-80 [8354563.001]
  • [Cites] Am J Surg Pathol. 1984 May;8(5):323-33 [6731662.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] Histopathology. 1987 Feb;11(2):209-14 [2437004.001]
  • [Cites] Cancer. 1980 Mar 1;45(5):919-27 [7260842.001]
  • [Cites] Hum Pathol. 1993 Dec;24(12):1298-305 [8276377.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):609-11 [17768664.001]
  • [Cites] Ann Diagn Pathol. 1999 Apr;3(2):75-80 [10196386.001]
  • [Cites] Semin Diagn Pathol. 1996 Nov;13(4):326-38 [8946610.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Semin Diagn Pathol. 2006 May;23(2):70-83 [17193820.001]
  • [Cites] Arch Pathol Lab Med. 1981 Jun;105(6):287-93 [6263212.001]
  • [Cites] Arch Pathol Lab Med. 1995 Dec;119(12):1173-6 [7503670.001]
  • [Cites] J Gastrointest Surg. 2005 Jul-Aug;9(6):822-5 [15985238.001]
  • [Cites] Surg Today. 2002;32(1):81-5 [11871825.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1598-604 [17895763.001]
  • [Cites] Am J Surg Pathol. 2005 Oct;29(10):1373-81 [16160481.001]
  • [Cites] Mil Med. 1992 Oct;157(10):559-61 [1454184.001]
  • (PMID = 18618258.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Krikelis D, Judson I: Role of chemotherapy in the management of soft tissue sarcomas. Expert Rev Anticancer Ther; 2010 Feb;10(2):249-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of chemotherapy in the management of soft tissue sarcomas.
  • Soft tissue sarcomas are a diverse group of rare tumors that comprise 1% of all cancers.
  • Few randomized trials of chemotherapy have been performed but there is a clear role for agents such as doxorubicin and ifosfamide in the palliation of advanced disease.
  • There is uncertainty as to whether sequential single-agent treatment is equivalent to combination chemotherapy.
  • For the majority of histological subtypes adjuvant chemotherapy is not of proven value, although there may be situations where it is advantageous.
  • However, there are other subtypes, such as the Ewing's sarcoma family tumors, for which chemotherapy is an essential part of primary management and has definitely improved survival.
  • Apart from Ewing's sarcoma family tumor and rhabdomyosarcoma, there is increasing specialization of chemotherapy according to histological subtype, such as the use of taxanes for angiosarcoma, gemcitabine and docetaxel for leiomyosarcoma, and trabectedin for leiomyosarcoma and liposarcoma, especially the myxoid/round cell variant.
  • Nevertheless, there are serious limitations to existing treatment and novel therapies need to be developed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20132000.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 105
  •  go-up   go-down


30. Carter NJ, Keam SJ: Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs; 2007;67(15):2257-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
  • Intravenous trabectedin administered once every 3 weeks is approved as monotherapy in Europe for use in patients with advanced soft tissue sarcoma (STS) after failure of standard therapy with anthracyclines or ifosfamide, or who are unsuited to receive these agents.
  • It also has orphan drug status in STS in the US and in ovarian cancer in the US and Europe, and is under investigation as combination therapy in patients with recurrent ovarian cancer.
  • In clinical trials, trabectedin showed efficacy in the treatment of patients with advanced or metastatic STS, especially those with leiomyosarcoma or liposarcoma, as well as in women with platinum-sensitive advanced or recurrent ovarian cancer.
  • The introduction of trabectedin expands the currently limited range of effective treatment options for patients with advanced or metastatic STS; trabectedin also has the potential to be a beneficial treatment for advanced or recurrent ovarian cancer.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / therapeutic use. Ovarian Neoplasms / drug therapy. Sarcoma / drug therapy. Tetrahydroisoquinolines / therapeutic use

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1998 Sep;9(9):981-7 [9818072.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Mol Cancer Ther. 2005 Feb;4(2):333-42 [15713904.001]
  • [Cites] J Med Chem. 2006 Nov 16;49(23 ):6925-9 [17154523.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8155-62 [16912194.001]
  • [Cites] Eur J Cancer. 2006 Jul;42(10 ):1484-90 [16737808.001]
  • [Cites] Invest New Drugs. 2006 Jan;24(1):3-14 [16379042.001]
  • [Cites] Drugs. 2002;62(8):1185-92; discussion 1193-4 [12010079.001]
  • [Cites] Biochem Pharmacol. 2003 Dec 15;66(12 ):2381-95 [14637196.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23 (24):5484-92 [16110008.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):323-33 [15661559.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):672-7 [15701855.001]
  • [Cites] Anticancer Drugs. 2005 Sep;16(8):811-5 [16096428.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12 ):2305-11 [14676811.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2964-71 [15805300.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5902-8 [14522916.001]
  • [Cites] Mol Pharmacol. 2005 Nov;68(5):1496-503 [15961672.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12 ):3893-903 [12473605.001]
  • [Cites] Eur J Cancer. 2004 Jun;40(9):1327-31 [15177491.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii74-6 [17491057.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3377-81 [12067978.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Invest New Drugs. 2007 Feb;25(1):1-7 [16633714.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):94-109 [15061599.001]
  • [Cites] Semin Oncol. 2007 Apr;34(2 Suppl 2):S1-15 [17512352.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 May;59(6):825-37 [16988825.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Oct;50(4):309-19 [12357306.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Lancet Oncol. 2007 Jul;8(7):595-602 [17586092.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Clin Cancer Res. 2010 May 1;16(9):2656-65 [20406837.001]
  • [Cites] Mayo Clin Proc. 2007 Jun;82(6):751-70 [17550756.001]
  • [Cites] Br J Cancer. 2006 Jun 5;94(11):1610-4 [16736024.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 6):S12-6 [16716798.001]
  • [Cites] Int J Gynecol Cancer. 2007 Jan-Feb;17(1):1-20 [17291226.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23 (3):576-84 [15659504.001]
  • [Cites] Int J Oncol. 2005 Dec;27(6):1605-16 [16273217.001]
  • [Cites] Ann Oncol. 2007 Apr;18 Suppl 2:ii12-4 [17491026.001]
  • [Cites] Curr Opin Oncol. 2006 Jul;18(4):347-53 [16721129.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23 (9):1867-74 [15774779.001]
  • [Cites] Curr Opin Oncol. 2007 Jul;19(4):336-40 [17545796.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):890-9 [14990645.001]
  • [Cites] Anticancer Drugs. 2005 Oct;16(9):935-43 [16162970.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12 ):4725-32 [11156226.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1920-6 [12932672.001]
  • [Cites] Cancer. 2003 Aug 15;98 (4):832-40 [12910529.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1480-90 [15084621.001]
  • [Cites] Lancet. 2003 Jun 21;361(9375):2099-106 [12826431.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2908-11 [11555609.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3251-7 [11595721.001]
  • (PMID = 17927287.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  • [Number-of-references] 80
  •  go-up   go-down


31. Dreinhöfer KE, Baldetorp B, Akerman M, Fernö M, Rydholm A, Gustafson P: DNA ploidy in soft tissue sarcoma: comparison of flow and image cytometry with clinical follow-up in 93 patients. Cytometry; 2002 Feb 15;50(1):19-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA ploidy in soft tissue sarcoma: comparison of flow and image cytometry with clinical follow-up in 93 patients.
  • In soft tissue sarcoma, the prognostic importance of DNA ploidy status is limited.
  • None of the patients had received preoperative radiotherapy or chemotherapy.
  • In 5 FCM type 1-2 tumors (diploid), the identification of non-diploid stemlines by ICM did not influence the metastatic rates.
  • Increasing tumor size, histotype other than liposarcoma, increasing malignancy grade, tumor necrosis, and ICM non-diploidy were univariate prognostic factors for metastasis.
  • [MeSH-major] DNA, Neoplasm / analysis. Flow Cytometry / methods. Image Cytometry / methods. Ploidies. Sarcoma / genetics. Soft Tissue Neoplasms / genetics

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11857594.001).
  • [ISSN] 0196-4763
  • [Journal-full-title] Cytometry
  • [ISO-abbreviation] Cytometry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


32. Cecchetto G, Alaggio R, Dall'Igna P, Bisogno G, Ferrari A, Gigante C, Casanova M, Sotti G, Zanetti I, Carli M: Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer; 2005 Nov 1;104(9):2006-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies.
  • BACKGROUND: Treatment of initially unresectable nonrhabdo soft tissue sarcomas (NRSTS) in pediatric age is debated, due to their different chemosensitivity.
  • The authors objective was to evaluate clinical features and treatment results observed in a series of Italian patients over a 24-year period.
  • Therapeutic guidelines recommended an initial biopsy plus neoadjuvant chemotherapy.
  • Aggressive delayed surgery of residual disease, including compartmental resections, was recommended.
  • Nonchemosensitive (CTns) sarcomas, 31: fibrosarcoma, 11; malignant peripheral nerve sheet tumors, 10; liposarcoma, 2; hemangiopericitoma adult type, 2; epithelioid sarcoma, 2; and alveolar soft part sarcoma, leiomyosarcoma, clear cell sarcoma, and sarcoma NOS, each 1.
  • Nineteen of 21 patients with CTs-NRSTS were alive without disease: the 5-year overall survival (OS) and progression-free survival (PFS) were 94.4% and 79.3%, respectively; 23 of 31 patients with CTns-NRSTS were alive without disease: 5-year OS and PFS were 75.3% and 68.3%, respectively.
  • Response to neoadjuvant chemotherapy was complete or partial in 10 of 20 evaluable CTs and in 8 of 26 evaluable CTns tumors.
  • Tumor size < 5 cm, distal site, and tumor grading for CTns sarcomas were often linked to a favorable outcome; no conclusive results were detected concerning age of the patients or T status of the tumor.
  • CONCLUSIONS: Multidisciplinary treatment without mutilating procedures allowed the cure of most patients with CTs and CTns-NRSTS.
  • [MeSH-major] Extremities. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Age Factors. Chemotherapy, Adjuvant. Child. Female. Humans. Italy. Male. Neoadjuvant Therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol; 2010 Dec;21(12):2436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database.
  • BACKGROUND: The predictive value of grade for benefit from adjuvant chemotherapy (AC) in soft tissue sarcoma (STS) patients has never been explored.
  • Grade was assessed according to the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) system after central review.
  • Young age, non-well-differentiated liposarcoma histology, deep location, bone and/or neurovascular invasion and grade 2 or 3 were significantly associated with a higher likelihood to receive AC.
  • CONCLUSION: This large cohort-based analysis with long-term follow-up indicates that patients with FNCLCC grade 3 disease may benefit from AC.

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20439343.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


34. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE: Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol; 2008 Jun;15(6):1585-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
  • BACKGROUND: Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly.
  • We hypothesized that WD and DD have distinct biological behaviors mandating different treatments.
  • A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001).
  • Only 3.7% WD recurred as high grade metastatic disease.
  • Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001).
  • Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection.
  • SYNOPSIS: The biological behaviors of well-differentiated and dedifferentiated liposarcomas differ significantly.
  • This article presents outcomes of two different surgical approaches that were implemented at the UTMDACC, treating these tumors as different disease entities.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jun;15(6):1555-6 [18347875.001]
  • (PMID = 18398663.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Calleja Subirán MC, Hernández Gutiérrez FJ, López Elzaurdia C, Revestido García R: [Liposarcoma histologic subtypes: four cases reports]. An Med Interna; 2007 Apr;24(4):179-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma histologic subtypes: four cases reports].
  • [Transliterated title] Subtipos histológicos de liposarcoma: presentación de cuatro casos.
  • The liposarcoma is a malignant tumor of mesodermic origin derived of the adipose tissue.
  • Liposarcoma s types, according to his histological diagnosis, are: mixoide, pleomorphic, well differentiated and dedifferentiated.
  • His treatment is the radical surgery, it is possible, together with radiation therapy and/or chemotherapy.
  • Four patients diagnosed of liposarcoma are shown up, a case of liposarcoma well differentiated, another case of liposarcoma pleomorphic and two cases about liposarcoma mixoide; with the characteristic that one of these two cases presented a local recidivation with a dediferenciation of itself.
  • [MeSH-major] Abdominal Neoplasms / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdomen / pathology. Aged. Diagnosis, Differential. Female. Humans. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / pathology. Liposarcoma, Myxoid / radiography. Liposarcoma, Myxoid / surgery. Male. Middle Aged. Prognosis. Radiography, Abdominal. Retroperitoneal Space / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867902.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


36. Oliveira AM, Nascimento AG: Pleomorphic liposarcoma. Semin Diagn Pathol; 2001 Nov;18(4):274-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic liposarcoma.
  • Pleomorphic liposarcoma (PLS) is defined as a high-grade pleomorphic sarcoma containing multivacuolated lipoblasts.
  • Older age, female sex, epithelioid phenotype, and radiotherapy or chemotherapy administration were not significantly associated with an adverse outcome.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757868.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 78
  •  go-up   go-down


37. Xu AX, Wang XX, Hong BF, Ye LY, Zhang L: [Non-epithelial tissue tumors of the urinary bladder]. Zhonghua Wai Ke Za Zhi; 2003 Jul;41(7):530-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-epithelial tissue tumors of the urinary bladder].
  • OBJECTIVE: To summarize the experience in the diagnosis and treatment of non-epithelial tissue tumor of urinary bladder.
  • METHODS: >From 1953 to April 2002, a total of 28 patients with non-epithelial tissue tumor in 3 925 bladder tumor cases were analyzed.
  • Ultrasonic examination, computed tomography (CT) scan, cystoscopy and biopsy is used for diagnosis of the tumor.
  • Seventeen of 28 patients (61.7%) were malignant neoplasms in 7 kinds of pathologic types, which was small cell carcinoma (5 cases), rhabdomyosarcoma (4 cases), leiomyosarcoma (4 cases), lymphoma (1 case), malignant fibrous histiocytoma (1 case), liposarcoma(1 case), melanoma (1 case) respectively.
  • Eleven of 28 patients (39.3%) were benign tumors with 4 kinds of histologic types including 2 cases of cavernous hemangioma, 1 case of fibroma, 1 case of leiomyoma, 7 cases of pheochromocytoma.
  • In 17 malignant neoplasms patients, 7 of them received partial cystectomy, 9 received radical cystectomy, and 1 patient's tumor was unresectable.
  • Those malignant bladder tumor patient are followed up, but 3 years survival rates is only 8/17.
  • CONCLUSIONS: Non-epithelial tissue tumor of the urinary bladder is rare with complicated pathologic types.
  • Malignant neoplasms are more than benign tumors with very poor prognosis, benign tumors' prognosis is good.
  • Diagnosis rate which was confirmed before operation is low.
  • Dip biopsy under cystoscopy may enhance the diagnosis rate.
  • Surgical treatment is the main therapy for non-epithelial tissue tumor of the urinary bladder.
  • Because of the aggressive biologic behavior of malignant tumors, they should be identified promptly and treated appropriately.
  • According to the histologic appearance radiotherapy and chemotherapy is mandatory in some cases.
  • [MeSH-major] Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Cystectomy / methods. Cystoscopy. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome. Urinary Bladder / pathology. Urinary Bladder / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12921662.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


38. Kostka R, Baitler T, Zachoval R, Sosna B, Palascak P: [Liposarcoma of the spermatic cord]. Prog Urol; 2006 Apr;16(2):215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord].
  • [Transliterated title] Liposarcome du cordon spermatique.
  • Liposarcoma of the spermatic cord is rare.
  • Value of adjuvant radiotherapy/chemotherapy remains uncertain.
  • We report on a 62 year old male who presented with a half a year history of a soft painless mass in the left scrotum extending from the groin up to the testis.
  • Histological examination revealed a well-differentiated liposarcoma of sclerosing subtype.
  • No evidence of recurrence or metastases has been noted during the 6-month and one year follow-up without any postoperative adjuvant therapy.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734250.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


39. Benaragama KS, Neequaye SK, Maudgil D, Gordon AG: Small bowel liposarcoma--a rare cause of small bowel perforation. BMJ Case Rep; 2010;2010
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel liposarcoma--a rare cause of small bowel perforation.
  • The histology demonstrated a well-differentiated liposarcoma.
  • Liposarcomas are the most common soft tissue sarcomas in adults but occurrence in the gastrointestinal tract is extremely rare.
  • Surgical resection with clear margins is the treatment of choice for primary liposarcomas.
  • They are moderately radiosensitive and chemotherapy is non-effective.
  • Although gastrointestinal liposarcomas have been previously reported, this is the first reported case of a primary liposarcoma associated with a small bowel perforation.
  • [MeSH-major] Ileal Neoplasms / diagnosis. Intestinal Perforation / etiology. Liposarcoma / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Ileal Diseases / diagnosis. Ileal Diseases / etiology. Male

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1975;(253):1-71 [1059326.001]
  • [Cites] Am J Gastroenterol. 1988 Jan;83(1):89-92 [3337069.001]
  • [Cites] Tumori. 1993 Apr 30;79(2):77-91 [8346570.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):389-94 [10379861.001]
  • [Cites] Int Surg. 1999 Apr-Jun;84(2):163-7 [10408290.001]
  • (PMID = 22791735.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029041
  •  go-up   go-down


40. Yokoi M, Hosokawa K, Funaki H, Yoshitani S, Kinami S, Omote K, Ueda N, Nakano Y, Kosaka T, Minato H: [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2114-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP].
  • A 53-year-old man was evaluated for a chief complaint of abdominal bloating.
  • The patient was diagnosed with retroperitoneal liposarcoma.
  • On histopathology, the dark red lesions showed dedifferentiated liposarcoma, and the yellowish lesions showed well-differentiated liposarcoma.
  • Despite VAC chemotherapy (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg), progressive disease (PD) was noted.
  • As second-line chemotherapy, weekly IFM (2 g)+CDDP (30 mg) was given.
  • This case suggests that IFM+CDDP may be useful in dedifferentiated liposarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


41. Ben Moualli S, Mnif A, Ben Amna M, Ben Hassine L, Chebil M, Zermani R, Ayed M: [Giant retroperitoneal liposarcoma: report of a case]. Ann Urol (Paris); 2002 Dec;36(6):372-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant retroperitoneal liposarcoma: report of a case].
  • [Transliterated title] Le liposarcome rétropéritonéal géant: à propos d'un cas.
  • Liposarcoma is a rare and primary malignancy developed from mesenchymal tissue.
  • We report the case of a 32-year-old woman who had a complete exeresis of a 15 cm retroperitoneal myxoid liposarcoma.
  • In 2000, a local recurrence and an intestinal localisation of the liposarcoma were observed.
  • The retroperitoneal tumor could not be removed and she had an intestinal resection followed by chemotherapy.
  • With the literature data, we review the pathological, therapeutic and prognostic aspects of this tumor.
  • [MeSH-major] Liposarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12611138.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 15
  •  go-up   go-down


42. Sugawara Y, Murase K, Kikuchi K, Sakayama K, Miyazaki T, Kajihara M, Miki H, Mochizuki T: Measurement of tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging and deconvolution analysis: a preliminary study in musculoskeletal tumors. J Comput Assist Tomogr; 2006 Nov-Dec;30(6):983-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 14 patients with malignant musculoskeletal tumors, TBF maps were generated pixel-by-pixel by deconvolution analysis.
  • In 14 patients with musculoskeletal tumors, TBF showed wide variances: the lowest of 9.6 mL.100 mL.min in liposarcoma and the highest of 182.0 mL.100 mL.min in osteosarcoma.
  • After chemotherapy, the TBF values (7.9, 11.0, and 11.7 mL.
  • [MeSH-major] Bone Neoplasms / blood supply. Bone Neoplasms / diagnosis. Magnetic Resonance Imaging. Muscle Neoplasms / blood supply. Muscle Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17082707.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


43. Moureau-Zabotto L, Thomas L, Bui BN, Chevreau C, Stockle E, Martel P, Bonneviale P, Marques B, Coindre JM, Kantor G, Matsuda T, Delannes M: [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases]. Cancer Radiother; 2004 Oct;8(5):279-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of soft tissue sarcomas in first isolated local recurrence: a retrospective study of 83 cases].
  • [Transliterated title] Prise en charge des sarcomes des tissus mous en première rechute locale isolée: étude rétrospective de 83 cas.
  • PURPOSE: To analyse the management and clinical outcome of patients treated for a first isolated local recurrence of soft tissue sarcoma (trunk or extremities) and to identify prognosis factors.
  • Histologic subtypes were mainly grade 2 (42%) or 3 (36%) histocytofibrosarcomas (49%) and liposarcomas (20%).
  • Surgical treatment of recurrences consisted in wide excision (32 cases), marginal resection (46 cases), five patients requiring amputation.
  • Beside surgery, six patients received neoadjuvant and seven others adjuvant chemotherapy.
  • Twenty-three patients received postoperative external beam radiotherapy (EBRT) (mean dose 55 Gy) and 26 interstitial (192)Ir low dose rate brachytherapy (BCT) (mean dose 45 Gy for BCT alone, 22 Gy when associated with EBRT), 19 patients being re-irradiated.
  • Nineteen patients developed secondary distant metastases.
  • Multivariate analysis showed trunk (P =0.0001) or inferior extremity locations (P =0.023), symptomatic (P =0.001), high grade (P =0.01), deep (P = 0.01) tumours, and the occurrence of a further local failure (P =0.004) as unfavourable characteristics for overall survival.
  • CONCLUSION: Because of the high relapse rate in this series, a first isolated local recurrence of STS increases mainly the risk of a subsequent local relapse.
  • Quality of local treatment for the first local relapse is decisive.
  • When a conservative treatment is feasible, it should combine surgical resection and radiotherapy, brachytherapy being the best suited in previously irradiated patients.
  • Efforts have to be pursued to increase quality of the treatment of primary tumours, at best performed in centers that have expertise in this field.
  • [MeSH-major] Neoplasm Recurrence, Local / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brachytherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Fibrosarcoma / radiotherapy. Fibrosarcoma / surgery. Follow-Up Studies. Humans. Liposarcoma / radiotherapy. Liposarcoma / surgery. Male. Middle Aged. Multivariate Analysis. Neoadjuvant Therapy. Postoperative Care. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Time Factors

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15561593.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


44. Yoo NJ, Kim HS, Kim SY, Park WS, Park CH, Jeon H, Jung ES, Lee JY, Lee SH: Immunohistochemical analysis of Smac/DIABLO expression in human carcinomas and sarcomas. APMIS; 2003 Mar;111(3):382-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alteration of apoptosis is essential for cancer development, and cancer cell death by radiation and chemotherapy is largely dependent upon apoptosis.
  • In this study, archival tissues of 100 carcinomas and 50 sarcomas from various origins were analyzed by immunohistochemistry for the expression of Smac/DIABLO.
  • Smac/DIABLO is expressed in 11 of 50 (22%) sarcomas, including 2 of 8 malignant schwannomas, 5 of 11 rhabdomyosarcomas, 2 of 7 malignant fibrous histiocytomas, 1 of 6 leiomyosarcomas, 0 of 8 angiosarcomas, 0 of 8 liposarcomas, and 1 of 2 Ewing's sarcomas.
  • These data demonstrated that Smac/DIABLO expression levels vary depending on the individual cancer types.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12752217.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins
  •  go-up   go-down


45. Hughes DT, Martel PM, Kinlaw WB, Eisenberg BL: The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells. Cancer Invest; 2008 Mar;26(2):118-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The synthetic triterpenoid CDDO-Im inhibits fatty acid synthase expression and has antiproliferative and proapoptotic effects in human liposarcoma cells.
  • Liposarcomas constitute a rare group of tumors of mesenchymal origin that are often poorly responsive to therapy.
  • This study characterizes a novel human liposarcoma cell line (LiSa-2) and defines the mechanism of its response to a synthetic triterpenoid.
  • Fatty acid synthase (FAS) is a key enzyme of de-novo fatty acid synthesis and is highly expressed in both human liposarcoma tissue specimens and LiSa-2 cells.
  • Treatment of the LiSa-2 cell line with the synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic imidazolide (CDDO-Im) markedly inhibited FAS mRNA expression, FAS protein production and FAS gene promoter activity.
  • Importantly, CDDO-Im produced a dose-dependent apoptotic effect in the LiSa-2 cell line, and simultaneous treatment with CDDO-Im and the fatty acid synthase inhibitor Cerulenin produced a synergistic cytotoxic effect.
  • Thus, CDDO-Im and Cerulenin act at different loci to inhibit long chain fatty acid synthesis in liposarcoma cells.
  • The observed dependence of liposarcomas on lipogenesis to support their growth and survival provides a novel approach to the treatment of liposarcomas with agents that target fatty acid production.
  • [MeSH-major] Apoptosis / drug effects. Cell Proliferation / drug effects. Fatty Acid Synthases / antagonists & inhibitors. Imidazoles / pharmacology. Liposarcoma / drug therapy. Oleanolic Acid / analogs & derivatives
  • [MeSH-minor] Adipocytes / cytology. Adipocytes / drug effects. Adipocytes / metabolism. Antigens, CD95 / genetics. Antigens, CD95 / metabolism. Blotting, Western. Cerulenin / pharmacology. Drug Synergism. Drug Therapy, Combination. Fatty Acid Synthesis Inhibitors / pharmacology. Glycerolphosphate Dehydrogenase / metabolism. Humans. Palmitic Acid / metabolism. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Liposarcoma.
  • Hazardous Substances Data Bank. PALMITIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36273-82 [16118208.001]
  • [Cites] J Lipid Res. 2005 Dec;46(12):2624-35 [16162944.001]
  • [Cites] Exp Cell Res. 2006 Feb 1;312(3):278-88 [16300755.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jul;98(2):231-40 [16552628.001]
  • [Cites] Nutrition. 2000 Mar;16(3):202-8 [10705076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3450-4 [10716717.001]
  • [Cites] Annu Rev Cell Dev Biol. 2000;16:145-71 [11031233.001]
  • [Cites] Mol Endocrinol. 2000 Oct;14(10):1550-6 [11043571.001]
  • [Cites] Int J Cancer. 2000 Dec 15;88(6):889-94 [11093810.001]
  • [Cites] Mol Pharmacol. 2001 May;59(5):1094-9 [11306692.001]
  • [Cites] Trends Mol Med. 2001 Sep;7(9):395-400 [11530334.001]
  • [Cites] Blood. 2002 Jan 1;99(1):326-35 [11756188.001]
  • [Cites] Biochem J. 2003 May 1;371(Pt 3):753-60 [12489982.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2798-806 [12855660.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5926-39 [14522919.001]
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1409-12 [14562008.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10715-20 [15235125.001]
  • [Cites] Bacteriol Rev. 1976 Sep;40(3):681-97 [791237.001]
  • [Cites] J Biol Chem. 1979 Jan 25;254(2):273-5 [762059.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Oct;76(10):5138-42 [291926.001]
  • [Cites] Biol Chem Hoppe Seyler. 1986 Sep;367(9):905-12 [3790257.001]
  • [Cites] Anal Biochem. 1990 Nov 15;191(1):31-4 [1706565.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83 [8022791.001]
  • [Cites] Cancer. 1994 Aug 15;74(4):1265-9 [8055448.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):211-44 [8000998.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12975-80 [9371785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6 [10097144.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):336-41 [9927043.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4611-5 [9788612.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7927-35 [15520199.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6719-25 [16061653.001]
  • (PMID = 18259941.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA126618
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole; 0 / Antigens, CD95; 0 / FAS protein, human; 0 / Fatty Acid Synthesis Inhibitors; 0 / Imidazoles; 17397-89-6 / Cerulenin; 2V16EO95H1 / Palmitic Acid; 6SMK8R7TGJ / Oleanolic Acid; EC 1.1.- / Glycerolphosphate Dehydrogenase; EC 2.3.1.85 / Fatty Acid Synthases
  • [Other-IDs] NLM/ NIHMS503932; NLM/ PMC3768287
  •  go-up   go-down


46. Kusuzaki K, Shinjo H, Murata H, Takeshita H, Hashiguchi S, Nozaki T, Emoto K, Ashihara T, Hirasawa Y: Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities. Anticancer Res; 2000 Sep-Oct;20(5C):3813-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between doxorubicin binding ability and tumor volume decrease after chemotherapy in adult malignant soft tissue tumors in the extremities.
  • We performed the present study to clarify the relationship between the DOX binding ability (%DB) and the histologic response, rate of decrease in tumor volume of malignant soft tissue tumors after preoperative chemotherapy and prognosis.
  • Nine malignant soft tissue tumors (4 liposarcomas, 3 synovial sarcomas, one malignant fibrous histiocytoma (MFH) and one extraskeletal osteosarcoma (EOS)) which arose at the extremities of adult patients were analyzed by the DOX binding assay using freshly biopsied specimens.
  • After preoperative chemotherapy including DOX or pirarubicin (THP), the rate of decrease in tumor volume was measured using magnetic resonance imaging, and the histologic response expressed as tumor necrosis to chemotherapy was also investigated.
  • All the patients, apart for one, were continuously disease-free after treatment.
  • One patient with EOS died of metastatic disease before surgery.
  • These results suggest that in malignant soft tissue tumors, the rate of decrease in tumor volume after chemotherapy might be a better indicator for chemosensitivity than the histologic response and also that the DOX binding ability might be a good predictor for chemosensitivity before chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / pharmacokinetics. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Arm. Carboplatin / administration & dosage. Chemotherapy, Adjuvant. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / pathology. Magnetic Resonance Imaging. Male. Middle Aged. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / pathology. Thigh

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11268459.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; D58G680W0G / pirarubicin
  •  go-up   go-down


47. Schwarzbach MH, Eisold S, Burguete T, Willeke F, Klein-Bauernschmitt P, Schlehofer JR, Herfarth C, Ridder R, von Knebel Doeberitz M: Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection. Int J Oncol; 2002 Jun;20(6):1211-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitization of sarcoma cells to doxorubicin treatment by concomitant wild-type adeno-associated virus type 2 (AAV-2) infection.
  • Doxorubicin-based chemotherapy is used in the treatment of sarcomas.
  • Recently, it has been reported that parvoviruses confer various antineoplastic properties to infected cells, and that adeno-associated virus type 2 (AAV-2) infection sensitizes malignant epithelial cells to radiation- or chemotherapy-based genotoxic treatment.
  • Thus, we analyzed whether AAV-2 infection leads to an improved efficacy of doxorubicin chemotherapy in malignant mesenchymal cells, using 13 human sarcoma cell lines.
  • Therapeutic effects were analyzed by measuring cell viability and proliferation (WST-1, colony forming, and propidium iodide assays).
  • AAV-2 infection strongly increased the efficacy of doxorubicin treatment in rhabdomyo-, fibro-, osteo- and chondrosarcoma cells in a dose-dependent manner.
  • This effect was not observed in liposarcoma and synovial sarcoma cells, although a susceptability to AAV-2 infection was documented.
  • Our results indicate that the sensitization effects towards genotoxic treatment exerted by non-pathogenic AAV-2 infection are not restricted to epithelial malignancies but may also be exploited for the improvement of chemotherapy in patients suffering from rhabdomyo-, fibro-, osteo-, or chondrosarcomas.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Dependovirus / physiology. Doxorubicin / pharmacology. Sarcoma / drug therapy
  • [MeSH-minor] Apoptosis / drug effects. Cell Division / drug effects. Cell Survival / drug effects. Humans. Tumor Cells, Cultured. Virus Replication

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12012001.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  •  go-up   go-down


48. Tomek S, Koestler W, Horak P, Grunt T, Brodowicz T, Pribill I, Halaschek J, Haller G, Wiltschke C, Zielinski CC, Krainer M: Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer; 2003 Jun;39(9):1318-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines.
  • Five human soft tissue sarcoma (STS) cell lines (HTB-82 rhabdomyosarcoma, HTB-91 fibrosarcoma, HTB-92 liposarcoma, HTB-93 synovial sarcoma and HTB-94 chondrosarcoma) were analysed for their sensitivity to tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and the function of the TRAIL apoptotic pathway in these cells.
  • These data suggest that TRAIL, either as a single agent or in combination with cytotoxic agents, might represent a new treatment option for advanced STS, which constitutes a largely chemotherapy-resistant disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis. Membrane Glycoproteins / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Apoptosis Regulatory Proteins. DNA Fragmentation. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Drug Synergism. Flow Cytometry. Humans. Immunohistochemistry. Paclitaxel / administration & dosage. RNA, Messenger / metabolism. Recombinant Proteins. Reverse Transcriptase Polymerase Chain Reaction. TNF-Related Apoptosis-Inducing Ligand. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12763223.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tumor Necrosis Factor-alpha; 0 / Tumor Suppressor Protein p53; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


49. Schwarzbach MH, Hohenberger P: Current concepts in the management of retroperitoneal soft tissue sarcoma. Recent Results Cancer Res; 2009;179:301-19
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current concepts in the management of retroperitoneal soft tissue sarcoma.
  • Soft tissue sarcomas (STS) in the retroperitoneum are usually diagnosed at the late stages.
  • Surgery is the mainstay of treatment.
  • Blood vessel replacement and a multivisceral en bloc approach improve the quality of resection.
  • Blood vessel involvement is stratified in type I (arterial and venous involvement), type II (arterial involvement), type III(venous involvement), and type IV (no vascular involvement).
  • Adjuvant and neoadjuvant treatment options (chemotherapy, targeted therapy, and radiation therapy) are currently being investigated.
  • A prospective randomized phase III trial has shown a positive effect of neoadjuvant chemotherapy combined with regional hyperthermia in disease-free survival, response rate, and local control.
  • Subsets of liposarcomas (myxoid and round cell type) are selectively responsive to novel drugs, such as trabectedin, a DNA-binding agent.
  • An international effort is required to improve the evidence level on multimodal treatment algorithms.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230548.001).
  • [ISSN] 0080-0015
  • [Journal-full-title] Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer
  • [ISO-abbreviation] Recent Results Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 60
  •  go-up   go-down


50. Tebes S, Cardosi R, Hoffman M: Liposarcoma complicating pregnancy. Gynecol Oncol; 2001 Dec;83(3):610-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma complicating pregnancy.
  • Malignancy is uncommon and only seven cases of liposarcoma have been reported in association with pregnancy.
  • CASE: We present a case of a pregnant patient who was diagnosed with an adnexal mass detected by ultrasound at 13 weeks gestation.
  • The mass was surgically removed postpartum, when it was found to be a liposarcoma.
  • Postoperatively she received chemotherapy but eventually succumbed to her disease.
  • CONCLUSIONS: Liposarcoma is rarely found in association with pregnancy and may follow an aggressive course.
  • [MeSH-major] Genital Neoplasms, Female. Liposarcoma. Pregnancy Complications, Neoplastic

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2001 Elsevier Science.
  • (PMID = 11733983.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O: Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene; 2002 Mar 28;21(14):2261-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas.
  • COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistant tumours.
  • Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common.

  • COS Scholar Universe. author profiles.
  • SciCrunch. HGNC: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948409.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB033071/ AF345651/ AL117237/ BG154169
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 5.2.1.- / Cyclophilins
  •  go-up   go-down


52. Anand Rajan KD, Subbarao KC, Agarwala S, Gupta SD: Mediastinal liposarcoma of mixed type in childhood: a report of a case with unusual histologic features. Indian J Pathol Microbiol; 2010 Jul-Sep;53(3):525-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal liposarcoma of mixed type in childhood: a report of a case with unusual histologic features.
  • We hereby report the occurrence of mediastinal liposarcoma in a 11-year-old female child.
  • Dyspnea and wheezing of long-standing duration were the presenting complaints and a preoperative biopsy failed to yield the diagnosis.
  • Histologic examination revealed heterogeneous areas with well-differentiated liposarcoma-like areas, areas resembling myxoid liposarcoma, and areas of dedifferentiation.
  • Liposarcomas in the mediastinum are extremely rare tumors of childhood and the present case showed unusual histologic features.
  • Complete surgical excision with clear surgical margins remains the primary modality of treatment, although chemotherapy and radiotherapy have been tried.
  • [MeSH-major] Liposarcoma / diagnosis. Liposarcoma / pathology. Mediastinal Neoplasms / diagnosis. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Child. Dyspnea / etiology. Female. Histocytochemistry. Humans. Microscopy. Radiography, Thoracic. Respiratory Sounds / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20699516.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


53. Gholami S, Jacobs CD, Kapp DS, Parast LM, Norton JA: The value of surgery for retroperitoneal sarcoma. Sarcoma; 2009;2009:605840
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Introduction. Retroperitoneal sarcomas are uncommon large malignant tumors.
  • Most were liposarcoma (44%) and high-grade (59%).
  • Thirty-eight patients had an initial complete resection; 15 (37%) developed recurrent sarcoma and 12 (80%) had a second complete resection.
  • Radiation therapy or chemotherapy had no significant impact on overall or recurrence-free survival.
  • Complete surgical resection is the treatment of choice for patients with initial and locally recurrent retroperitoneal sarcoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):859-68 [8622034.001]
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Curr Treat Options Oncol. 2000 Aug;1(3):274-8 [12057171.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):468-73 [12393986.001]
  • [Cites] Arch Surg. 2003 Mar;138(3):248-51 [12611567.001]
  • [Cites] Ann Surg. 2003 Sep;238(3):358-70; discussion 370-1 [14501502.001]
  • [Cites] Oncology. 2003;65 Suppl 2:80-4 [14586155.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):483-90 [15078637.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):234-8 [17081725.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):31-7 [19047280.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):51-9 [2363604.001]
  • [Cites] Arch Surg. 1995 Oct;130(10):1104-9 [7575124.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):137-42 [19106689.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • (PMID = 19826633.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009337
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC2760213
  •  go-up   go-down


54. Farah M, Abou-Sleiman P, Bahous J: Primary mediastinal liposarcoma: a case report and review of the literature. J Med Liban; 2001 May-Jun;49(3):165-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mediastinal liposarcoma: a case report and review of the literature.
  • A case of mediastinal liposarcoma (LPS) in a 49-year-old female is described.
  • The radiologic features are nonspecific but are suggestive of the diagnosis.
  • A tissue biopsy is needed for the final diagnosis.
  • The treatment of choice is surgical with wide margin resection.
  • Chemotherapy and radiotherapy are ineffective modalities, used in unresectable or incompletely resected tumors.
  • [MeSH-major] Liposarcoma / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12184463.001).
  • [ISSN] 0023-9852
  • [Journal-full-title] Le Journal médical libanais. The Lebanese medical journal
  • [ISO-abbreviation] J Med Liban
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Lebanon
  •  go-up   go-down


55. Colwell AS, D'Cunha J, Vargas SO, Parker B, Dal Cin P, Maddaus MA: Synovial sarcoma of the pleura: a clinical and pathologic study of three cases. J Thorac Cardiovasc Surg; 2002 Oct;124(4):828-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial sarcomas are rare soft tissue malignancies that most commonly affect the extremities in the vicinity of large joints.
  • A variety of pleural cavity sarcomas have been described, including liposarcoma,(3) chondrosarcoma,(4) osteosarcoma,(5) and malignant schwannoma.(6) Pleural synovial sarcoma, however, is a much rarer entity.
  • Because of its rarity, pleural synovial sarcoma is often mistaken for the histologically similar malignant mesothelioma, the most common of the pleural neoplasms.
  • Studies in the last 10 years have shown it to be extremely sensitive to ifosfamide-based chemotherapy, and survival of patients with synovial sarcoma has recently increased with chemotherapy, with 5-year survivals now as high as 57%.(8-10) In this report, we describe 3 cases of synovial sarcoma of the pleura.
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. In Situ Hybridization, Fluorescence. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12324743.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Casali PG, Sanfilippo R, D'Incalci M: Trabectedin therapy for sarcomas. Curr Opin Oncol; 2010 Jul;22(4):342-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin therapy for sarcomas.
  • PURPOSE OF REVIEW: The therapeutic armamentarium of adult soft-tissue sarcomas (STS) has widened in recent years.
  • RECENT FINDINGS: Trabectedin has proven efficacy in STS, mainly in leiomyosarcomas, liposarcomas, and other translocation-related sarcomas.
  • Moreover, it exerts special antitumor activity in myxoid liposarcomas, with distinct patterns of tumor response.
  • Also, its mechanism of action is distinct in myxoid liposarcoma, apparently overcoming lipogenic cell differentiation block due to the tumor chromosomal translocation.
  • Occasional major myelosuppression is possible but proper patient selection (with a focus on liver tests) and possibly steroid premedication are of help.
  • SUMMARY: Trabectedin is a new marine-derived drug with a definite role in the 'histology-driven' medical therapy of STS.
  • [MeSH-major] Dioxoles / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tetrahydroisoquinolines / therapeutic use
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / therapeutic use. Disease-Free Survival. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20489618.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  • [Number-of-references] 43
  •  go-up   go-down


57. Msaad S, Yangui I, Ayedi L, Ketata W, Sellami T, Ayoub A, Jlidi R: [A rare primary tumor of the mediastinum: pleomorphic liposarcoma]. Rev Pneumol Clin; 2007 Dec;63(6):373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A rare primary tumor of the mediastinum: pleomorphic liposarcoma].
  • [Transliterated title] Une tumeur primitive rare du médiastin: le liposarcome pléomorphe.
  • Liposarcoma of the mediastinum is a rare tumor with various histologic features.
  • We report a case of mediatinal pleomorphic liposarcoma in a 37-year-old man who complained of chest pain.
  • Computed tomography showed an anterior expansive process within the mediastinum.
  • Histological diagnosis was established by a trans-thoracic computed tomography guided core-needle biopsy.
  • Despite a first cure of chemotherapy with gemcitabin/cisplatin, disease progression led to death 3 months after diagnosis.
  • Mediastinal pleomorphic liposarcoma is an exceptional invading tumor affecting the middle-aged adult.
  • Surgery is the best treatment when possible.
  • The role of radiotherapy and chemotherapy are discussed.
  • [MeSH-major] Liposarcoma / pathology. Mediastinal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chest Pain / etiology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Fatal Outcome. Humans. Male

  • Genetic Alliance. consumer health - Liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166943.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


58. Madge SN, Tumuluri K, Strianese D, Bonavolonta P, Wilcsek G, Dodd TJ, Selva D: Primary orbital liposarcoma. Ophthalmology; 2010 Mar;117(3):606-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary orbital liposarcoma.
  • PURPOSE: To describe 6 new cases of primary orbital liposarcoma and provide a review of the relevant literature.
  • PARTICIPANTS: Six patients with primary orbital liposarcoma.
  • MAIN OUTCOME MEASURES: Patient demographics; clinical presentations; results of radiologic imaging; histopathology; surgical techniques used and their complications; other treatment modalities; outcomes and recurrences.
  • RESULTS: Six cases of primary orbital liposarcoma were identified, 5 of which were primary presentations and 1 of which was a recurrence.
  • In 4 cases, exenteration was deferred, resulting in recurrence of disease in all 4.
  • Literature review identified 34 other cases of primary orbital liposarcoma, which, partly because of its rarity, is frequently initially misdiagnosed.
  • The most common subtype is myxoid (56.8%); other types are pleomorphic (10.8%) and well differentiated (29.7%).
  • Although radiotherapy has an established role in the treatment of nonorbital liposarcoma, the role of both radiotherapy and chemotherapy in the management of primary orbital liposarcoma is still unclear.
  • CONCLUSIONS: Orbital liposarcoma remains a diagnostic and surgical challenge.
  • Exenteration remains the treatment of choice, but clinicians must also be aware that liposarcoma may herald the diagnosis of the Li-Fraumeni familial cancer syndrome.
  • [MeSH-major] Liposarcoma / pathology. Neoplasm Recurrence, Local / diagnosis. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Male. Orbit Evisceration. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20022639.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Gacem K, Vachon L, Benard T, Delaire C, Bouvier JM: [Right atrioventricular metastasis of a myxoid liposarcoma. Case report and al review of the literature]. Arch Mal Coeur Vaiss; 2000 Sep;93(9):1155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Right atrioventricular metastasis of a myxoid liposarcoma. Case report and al review of the literature].
  • [Transliterated title] Métastase auriculo-ventriculaire droite d'un liposarcome myxoïde. A propos d'un cas et revue de la littérature.
  • Malignant tumours of the heart and pericardium are rare.
  • Secondary tumours are 20 to 40 times more common than primary tumours.
  • The authors report the case of a cardiac metastasis of a myxoid liposarcoma of the inguinal region.
  • Surgical ablation with chemotherapy significantly improved the patient' clinical and haemodynamic status.
  • A review of the literature shows that postoperative survival does not exceed 2 years, but the prognosis is better when chemotherapy is associated with surgery.
  • [MeSH-major] Abdominal Neoplasms / pathology. Heart Neoplasms / secondary. Liposarcoma, Myxoid / secondary

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11055008.001).
  • [ISSN] 0003-9683
  • [Journal-full-title] Archives des maladies du coeur et des vaisseaux
  • [ISO-abbreviation] Arch Mal Coeur Vaiss
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


60. Saad R Jr, Dorgan Neto V, Gonçalves R, Botter M, Siqueira LC: [Mediastinal liposarcoma: a case report]. J Bras Pneumol; 2008 Jan;34(1):55-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal liposarcoma: a case report].
  • [Transliterated title] Lipossarcoma de mediastino: relato de caso.
  • Here, we describe the case of a 51-year-old female with mediastinal liposarcoma.
  • Liposarcoma is the most common malignant mesenchymal neoplasm in adults, although a mediastinal location is extremely rare.
  • Computed tomography and magnetic resonance imaging provide useful data for diagnosis.
  • Tissue biopsy and histological typing are very important in determining the treatment and are needed for the final diagnosis.
  • Radiotherapy and chemotherapy are ineffective treatment modalities.
  • According to the literature, surgical resection is the treatment of choice.
  • [MeSH-major] Liposarcoma / diagnosis. Mediastinal Neoplasms / diagnosis
  • [MeSH-minor] Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Spectroscopy. Middle Aged. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278377.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


61. May M, Seehafer M, Helke C, Gunia S, Hoschke B: [Liposarcoma of the spermatic cord--report of one new case and review of the literature]. Aktuelle Urol; 2004 Apr;35(2):130-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord--report of one new case and review of the literature].
  • [Transliterated title] Liposarkom des Samenstrangs--Darstellung eines Falls.
  • Liposarcoma of the spermatic cord is a rare entity.
  • Although most liposarcomas of the spermatic cord are well-differentiated, the propensity for local recurrence is high.
  • Preferential treatment of spermatic cord liposarcoma is radical orchiectomy with high ligation of the cord.
  • Radiation therapy is recommended in addition to surgery in cases with evidence of more aggressive tumour behavior (i.e., high-grade tumour, lymphatic invasion, inadequate margin, or recurrence).
  • A 39-year-old-male presented with a 4-year history of a mass in the left scrotum.
  • Pathological analysis demonstrated a well-differentiated liposarcoma with tumour detection in the surgical margin.
  • Without any postoperative adjuvant therapy in evidence of recurrence or metastasis was noted during the 12-month follow-up period.
  • The current literature on management of malignant tumours of the spermatic cord is reviewed.
  • Paratesticular liposarcomas are most commonly well-differentiated and lipoma-like and have a prolonged clinical course.
  • Radical orchiectomy with wide local excision of the mass is the recommended therapy, while adjuvant radiotherapy may be considered in high-grade tumours and in recurrent liposarcomas.
  • Retroperitoneal lymphadenectomy does not offer any additional therapeutic benefit, and the role of chemotherapy is not well defined.
  • Regardless of initial therapy, the risk of local recurrence always necessitates long-term followup.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Orchiectomy. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15146377.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


62. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol; 2009 Sep 1;27(25):4188-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
  • PURPOSE: To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide.
  • PATIENTS AND METHODS: Patients were randomly assigned to one of two trabectedin regimens (via central venous access): 1.5 mg/m(2) 24-hour intravenous infusion once every 3 weeks (q3 weeks 24-hour) versus 0.58 mg/m(2) 3-hour IV infusion every week for 3 weeks of a 4-week cycle (qwk 3-hour).
  • Time to progression (TTP) was the primary efficacy end point, based on confirmed independent review of images.
  • CONCLUSION: Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy.
  • This trial documents superior disease control with the q3 weeks 24-hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also demonstrated activity relative to historical comparisons.
  • Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / administration & dosage. Drug Resistance, Neoplasm. Ifosfamide / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Tetrahydroisoquinolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia. Disease-Free Survival. Drug Administration Schedule. Europe. Female. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. North America. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Failure. Young Adult


63. Lafferty-Whyte K, Bilsland A, Cairney CJ, Hanley L, Jamieson NB, Zaffaroni N, Oien KA, Burns S, Roffey J, Boyd SM, Keith WN: Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma. BMC Genomics; 2010 Oct 01;11:532
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in peritoneal mesothelioma.
  • BACKGROUND: Cellular senescence is a major barrier to tumour progression, though its role in pathogenesis of cancer and other diseases is poorly understood in vivo.
  • Improved understanding of the degree to which latent senescence signalling persists in tumours might identify intervention strategies to provoke "accelerated senescence" responses as a therapeutic outcome.
  • Recent discovery of several new markers allows for an expression profiling approach to study specific senescence phenotypes in relevant tissue samples.
  • RESULTS: We first show that scoring captures differential induction of damage or inflammatory pathways in a series of public datasets involving radiotherapy of colon adenocarcinoma, chemotherapy of breast cancer cells, replicative senescence of mesenchymal stem cells, and progression of melanoma.
  • Scoring of our own mesenchymal tumour dataset highlighted differential expression of secretory signalling pathways between distinct subgroups of MPNST, liposarcomas and peritoneal mesothelioma.
  • [MeSH-major] Antineoplastic Agents / toxicity. Cell Aging / genetics. Gene Expression Regulation, Neoplastic / drug effects. Inflammation / genetics. Mesothelioma / genetics. Peritoneal Neoplasms / genetics. Signal Transduction / genetics
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Breast Neoplasms / radiotherapy. Cell Line, Tumor. Cluster Analysis. Databases, Genetic. Disease Progression. Female. Gene Expression Profiling. Humans. Mesenchymal Stromal Cells / drug effects. Mesenchymal Stromal Cells / metabolism. Prognosis. Research Design. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2006 Mar 24;124(6):1169-81 [16564011.001]
  • [Cites] Hum Mol Genet. 2006 Mar 1;15(5):725-33 [16421168.001]
  • [Cites] PLoS One. 2009;4(7):e6459 [19649288.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Histopathology. 2001 Aug;39(2):187-97 [11493336.001]
  • [Cites] Cancer Cell. 2010 Mar 16;17(3):262-72 [20227040.001]
  • [Cites] Int J Radiat Biol. 2005 Jun;81(6):445-58 [16308915.001]
  • [Cites] Environ Health Perspect. 2004 Nov;112(16):1607-13 [15598611.001]
  • [Cites] Cancer Biol Ther. 2008 Mar;7(3):392-6 [18075305.001]
  • [Cites] PLoS Biol. 2008 Dec 2;6(12):2853-68 [19053174.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2795-803 [15805280.001]
  • [Cites] Clin J Am Soc Nephrol. 2010 Jan;5(1):56-61 [19833906.001]
  • [Cites] Mol Divers. 2006 Feb;10(1):39-79 [16404528.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2881-4 [16540631.001]
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):339-44 [12114022.001]
  • [Cites] EMBO Rep. 2009 Mar;10(3):228-30 [19218920.001]
  • [Cites] Mech Ageing Dev. 2009 Jan-Feb;130(1-2):24-32 [18538372.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11299-304 [18695223.001]
  • [Cites] Curr Opin Cell Biol. 2008 Apr;20(2):150-5 [18353625.001]
  • [Cites] Nat Cell Biol. 2009 Aug;11(8):973-9 [19597488.001]
  • [Cites] Annu Rev Genet. 2008;42:301-34 [18680434.001]
  • [Cites] J Pathol. 2005 Dec;207(4):410-21 [16177957.001]
  • [Cites] FEBS Lett. 2008 Apr 30;582(10):1451-8 [18381073.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Sep;8(9):729-40 [17667954.001]
  • [Cites] Eur J Cancer. 2009 Aug;45(12):2138-45 [19409772.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):686-91 [17311013.001]
  • [Cites] Nat Rev Cancer. 2006 Jun;6(6):472-6 [16723993.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):236-44 [10700175.001]
  • [Cites] Pigment Cell Melanoma Res. 2008 Feb;21(1):27-38 [18353141.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Exp Cell Res. 2008 Jun 10;314(9):1909-17 [18423606.001]
  • [Cites] Cell. 2008 Jun 13;133(6):1019-31 [18555778.001]
  • [Cites] PLoS Biol. 2007 May;5(5):e110 [17472436.001]
  • [Cites] Life Sci. 2008 Sep 26;83(13-14):475-80 [18723031.001]
  • [Cites] Dev Cell. 2005 Jan;8(1):19-30 [15621527.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3303-8 [15867227.001]
  • [Cites] PLoS One. 2008;3(5):e2213 [18493317.001]
  • [Cites] Oncogene. 2009 Oct 29;28(43):3765-74 [19684619.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4134-40 [18593991.001]
  • [Cites] Biochem Pharmacol. 2008 Oct 15;76(8):947-57 [18657518.001]
  • [Cites] Aging Cell. 2010 Apr;9(2):220-35 [20089118.001]
  • [Cites] Mol Oncol. 2010 Feb;4(1):52-64 [19969511.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):1018-29 [16251803.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(6):2343-58 [17242207.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):5975-87 [18711403.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Genes Dev. 2009 Apr 1;23(7):798-803 [19279323.001]
  • [Cites] Neoplasia. 2010 May;12(5):405-14 [20454512.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):41-4 [10732785.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Cancer Inform. 2007 Feb 04;3:11-7 [19455231.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):111-8 [16871885.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1467-74 [18414473.001]
  • (PMID = 20920304.001).
  • [ISSN] 1471-2164
  • [Journal-full-title] BMC genomics
  • [ISO-abbreviation] BMC Genomics
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CAF/06/24; United Kingdom / Cancer Research UK / / F2-2007-200950
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC3091681
  •  go-up   go-down


64. Tehrani AH, Heegaard S, Prause JU, Fledelius HC, Daugaard S: Liposarcoma metastatic to the orbit. Eur J Ophthalmol; 2003 Jan-Feb;13(1):108-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma metastatic to the orbit.
  • PURPOSE: To describe a patient with liposarcoma metastatic to the left orbit.
  • Previously, a retroperitoneal liposarcoma had been surgically removed followed by postoperative radiation.
  • Trans-septal orbital biopsies showed liposarcoma.
  • The patient was initially treated with prednisolone and later received radio- and chemotherapy.
  • Despite treatment he lost vision of the left eye and died a few months later.
  • RESULTS: Histological examination of the orbital tumor revealed a spindle-cell liposarcoma similar to the primary tumor of the retroperitoneum.
  • CONCLUSIONS: Liposarcoma metastatic to the orbit is rare, but should be suspected in a patient with proptosis caused by a space-occupying lesion and a history of liposarcoma.
  • [MeSH-major] Liposarcoma / secondary. Orbital Neoplasms / secondary. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Combined Modality Therapy. Diplopia / etiology. Fatal Outcome. Humans. Ifosfamide / therapeutic use. Male. Radiotherapy, Adjuvant. Tomography, X-Ray Computed. Visual Acuity

  • Genetic Alliance. consumer health - Liposarcoma.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635688.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


65. Marom EM, Goodman PC: Double-ring esophageal sign: pathognomonic for esophageal lipomatosis. J Comput Assist Tomogr; 2002 Jul-Aug;26(4):584-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its typical CT features should lead to the correct diagnosis and be differentiated from other fatty lesions known to involve the esophagus, namely, lipoma and liposarcoma.
  • [MeSH-major] Esophageal Diseases / radiography. Esophagus / radiography. Lipomatosis / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Administration, Inhalation. Adrenal Cortex Hormones / adverse effects. Adrenal Cortex Hormones / therapeutic use. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pulmonary Disease, Chronic Obstructive / drug therapy. Pulmonary Disease, Chronic Obstructive / radiography

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Esophagus Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12218824.001).
  • [ISSN] 0363-8715
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


66. Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol; 2001 Mar 01;19(5):1256-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3 weeks to patients with treatment-refractory solid tumors.
  • Severe toxicities and DLTs were observed in patients with poor PS or abnormal liver function or who had received a large number of previous chemotherapy regimens.
  • Antitumor activity was observed at the three highest DLs, including three partial responses (breast cancer, osteosarcoma, and liposarcoma), and four patients (all with progressing soft tissue sarcomas) had stable disease lasting > or = 3 months.
  • CONCLUSION: The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Dioxoles / administration & dosage. Isoquinolines / administration & dosage. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Area Under Curve. Dose-Response Relationship, Drug. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Neutropenia / chemically induced. Tetrahydroisoquinolines. Thrombocytopenia / chemically induced

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11230466.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Isoquinolines; 0 / Tetrahydroisoquinolines; ID0YZQ2TCP / trabectedin
  •  go-up   go-down


67. Douchamps F, Kurth W, Crielaard JM: [Myxoid liposarcoma]. Rev Med Liege; 2009 Jul-Aug;64(7-8):403-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Myxoid liposarcoma].
  • [Transliterated title] Un liposarcome myxoïde.
  • Soft-tissue sarcoma is a rare pathology.
  • Due to restricted symptomatology, the diagnosis is often late.
  • Any soft tissues swelling requires at first an ultrasound exam and a radiography, though MRI remains the most appropriate investigation.
  • Treatment will be selected according to the tumor type and its histological grading, these parameters being determined after a surgical or a needle biopsy.
  • The surgical care is often complemented by radiotherapy and sometimes chemotherapy.
  • [MeSH-major] Knee / pathology. Liposarcoma, Myxoid / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Myxoid liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19777921.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


68. Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas. Bone Marrow Transplant; 2004 Jul;34(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.
  • The role of high-dose chemotherapy (HDCT) with PBSCT in the treatment of bone and soft-tissue sarcomas is not established.
  • In total, 27 patients (15 female, median age at TPL 30.6 years (range: 13-59)) were analyzed (Ewing sarcoma family n=8, osteosarcoma n=6, MPNST (malignant peripheral nerve sheath tumor) n=4, synovial sarcoma n=3, liposarcoma n=2, leiomyosarcoma n=2, rhabdomyosarcoma n=1, meningosarcoma n=1).
  • Following chemotherapy and surgery complete remission (CR) (n=9), partial remission (PR) (n=10), stable disease (SD) (n=2) and progressive disease (PD) (n=6) were reached prior HDCT.
  • Four patients died within 6 months due to PD, disease recurred in another seven patients and led to death, 15 patients are alive with/without disease.
  • Although the role of HDCT in the treatment of sarcomas is not defined, a subgroup of patients who achieved CR before HDCT could benefit from this therapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / therapy. Peripheral Blood Stem Cell Transplantation / methods. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome


69. Ishiguro S, Yamamoto S, Chuman H, Moriya Y: A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide. Jpn J Clin Oncol; 2006 Nov;36(11):735-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide.
  • Primary mesenteric liposarcoma is a rare entity that has been reported only 14 times in English literature.
  • The treatment strategy for mesenteric liposarcoma is, if no distant metastases are detected, surgical resection with a wide surgical margin, often followed by radiation and/or adjuvant chemotherapy for high-risk patients.
  • However, the efficacy of pre-operative chemotherapy is unknown.
  • If the tumor is shrunk by pre-operative chemotherapy, we could achieve complete surgical resection, which is difficult when the tumor is too large or is invading neighboring organs.
  • We herein describe a case of huge mesenteric liposarcoma that showed significant tumor shrinkage by pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide, allowing a margin-negative operation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Mesentery. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000700.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


70. Bowles KM, Tooze R, Marcus RE: Large-cell lymphoma. An unusual late relapse. Clin Lab Haematol; 2001 Jun;23(3):197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 40-year-old man with a stage 4, anaplastic, large-cell lymphoma.
  • He had been diagnosed 13 years before as having a liposarcoma, at which point he was treated with combination chemotherapy, which included anthracycline.
  • On review of the histopathology from 13 years before, the original diagnosis of liposarcoma was revised to that of an anaplastic large-cell lymphoma.
  • A diagnosis of relapsed anaplastic large-cell lymphoma was made.
  • Our patient responded initially to combination chemotherapy, which included anthracycline, without further reduction in his ejection fraction.
  • This was followed by high-dose chemotherapy and peripheral blood stem-cell transplantation.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / therapy
  • [MeSH-minor] Adult. Anthracyclines / administration & dosage. Anthracyclines / toxicity. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Diagnostic Errors. Heart Diseases / chemically induced. Hematopoietic Stem Cell Transplantation. Humans. Male. Recurrence. Remission Induction. Stroke Volume

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11553063.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antigens, CD30; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


71. Candela G, Di Libero L, Varriale S, Manetta F, Giordano M, Lanza M, Argenziano G, Pizza A, Sciascia V, Napolitano S, Riccio M, Esposito D, Santini L: [Diagnostic and therapeutic guidelines for entero-cutaneous fistulas. Personal experience and literature review]. Minerva Chir; 2007 Aug;62(4):293-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic and therapeutic guidelines for entero-cutaneous fistulas. Personal experience and literature review].
  • They can occur spontaneously, or after an injury or a surgical procedure.
  • They are associated with a high rate of morbidity and mortality.
  • Spontaneous fistulas can mainly occur in patients affected by cancer, inflammatory bowel disease, diverticulitis, appendicitis, as a result of radiotherapy or injuries.
  • Surgical procedures, carried out in case of neoplastic diseases, inflammatory bowel disease, adhesions removal, represent the primary cause in the development of a postoperative fistulas.
  • The experience reported here is about three ECF cases occurred after surgery and treated only with medical therapy.
  • The first case is a woman in good general conditions who underwent surgery to remove a recurrent retroperitoneal myxoid liposarcoma situated in the right lower quadrant.
  • The other two patients analyzed were affected by sepsis and metabolic unbalance and had developed a fistula after colonic resection.
  • Fluids and electrolytes adjustments and sepsis management have preceded any other kind of therapy.
  • In order to heal and protect peri-fistula skin we have used sterile washing solutions, absorbable ionic exchange resin, silver and polyurethanes based medications and colostomy bags adhesive systems.
  • Since surgical treatment of ECF is associated with high rates of morbidity and mortality, conservative treatment should always be taken into consideration.
  • When conservative treatment fails, delayed surgical intervention has been related to a higher rate of success.
  • The purpose of this study is to describe diagnostic and therapeutic guidelines to general surgeons, like ourselves, whenever they have to deal with ECF cases.
  • [MeSH-major] Colostomy. Intestinal Fistula / diagnosis. Intestinal Fistula / drug therapy
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antidiarrheals / therapeutic use. Disinfectants. Drug Therapy, Combination. Female. Hormones / therapeutic use. Humans. Loperamide / therapeutic use. Male. Middle Aged. Myxosarcoma / surgery. Polyurethanes. Practice Guidelines as Topic. Proton Pump Inhibitors. Retroperitoneal Neoplasms / surgery. Risk Factors. Sepsis / complications. Sepsis / therapy. Somatostatin / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17641589.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antidiarrheals; 0 / Disinfectants; 0 / Hormones; 0 / Polyurethanes; 0 / Proton Pump Inhibitors; 51110-01-1 / Somatostatin; 6X9OC3H4II / Loperamide
  • [Number-of-references] 47
  •  go-up   go-down


72. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer; 2007 Jul 1;121(1):199-205
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
  • However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent.
  • The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus.
  • We have therefore investigated the molecular response to Nutlin treatment in several liposarcoma cell lines with such markers, as well as a panel of other sarcoma cell lines.
  • We report that Nutlin efficiently stabilized p53 and induced downstream p53 dependent transcription and apoptosis in liposarcoma cells with amplified MDM2 in vitro.
  • Thus, Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
  • [MeSH-major] Imidazoles / pharmacology. Liposarcoma / drug therapy. Liposarcoma / pathology. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Genotype. Humans. Sensitivity and Specificity. Signal Transduction. Tumor Suppressor Protein p53 / metabolism


73. Levine PH, Wei XJ, Gagner JP, Flax H, Mittal K, Blank SV: Pleomorphic liposarcoma of the uterus: case report and literature review. Int J Gynecol Pathol; 2003 Oct;22(4):407-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic liposarcoma of the uterus: case report and literature review.
  • A 62-year-old woman with a history of breast carcinoma being treated with tamoxifen presented with a rapidly enlarging pelvic mass.
  • Microscopic examination revealed a variety of patterns and cell types characteristic of liposarcoma that included myxoid/round cell, storiform/pleomorphic, epithelioid, and spindle cell areas.
  • Although a variety of uterine tumors have been associated with tamoxifen treatment, this appears to be the first example of tamoxifen-associated uterine liposarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Liposarcoma / chemically induced. Liposarcoma / pathology. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / pathology
  • [MeSH-minor] Breast Neoplasms / drug therapy. Breast Neoplasms / prevention & control. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / prevention & control

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14501826.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 29
  •  go-up   go-down


74. Wolden SL, Alektiar KM: Sarcomas across the age spectrum. Semin Radiat Oncol; 2010 Jan;20(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, different types of sarcomas are most typical in these populations, and our understanding of these cancers in one group has provided direction for understanding them in the other group.
  • For example, advances at the molecular level in Ewing sarcoma, a disease that affects predominantly children, helped spearhead the uncovering of several signature translocations in adult sarcomas, such as synovial sarcoma and myxoid liposarcomas.
  • The success of chemotherapy in pediatric sarcomas continues to be a benchmark for adult sarcomas to emulate.
  • Conversely, the demonstration of the viability of limb-sparing surgery combined with adjuvant radiation in adult extremity sarcomas helped advance that treatment approach in pediatric sarcomas.
  • To illustrate some of these concepts and to enhance our understanding of sarcomas across the age spectrum, 4 types of sarcoma are discussed.
  • The other 2 are synovial sarcoma, which can be looked at as a bridge between pediatric and adult sarcomas as it affects mainly young adults, and liposarcoma that is almost exclusively an adult sarcoma.
  • [MeSH-major] Sarcoma / epidemiology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Combined Modality Therapy / methods. Female. Humans. Infant. Infant, Newborn. Liposarcoma / epidemiology. Liposarcoma / therapy. Male. Middle Aged. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / epidemiology. Sarcoma, Ewing / therapy. Sarcoma, Synovial / epidemiology. Sarcoma, Synovial / therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19959030.001).
  • [ISSN] 1532-9461
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


75. Pires de Camargo V, van de Rijn M, Maestro R, de Alava E, Madoz-Gúrpide J, Pilotti S, von Mehren M, Pedeutour F, Maki RG, Rutkowski P, Thomas DM: Other targetable sarcomas. Semin Oncol; 2009 Aug;36(4):358-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite complex genetics, aneuploid tumors like dedifferentiated liposarcoma have specific and reproducible chromosomal changes such as amplification of HDM2 and CDK4 that represent potential targets for systemic therapy.
  • In addition, there are cancer cell survival pathways that may not be the target of chromosomal translocations or mutations that are still estimable targets for new systemic therapeutics, be it pathways involved in angiogenesis or apoptosis.
  • In this review, we examine target selection for specific sarcoma subtypes, and demonstrate with a few examples new techniques being used to delineate novel therapeutic inroads for patients with sarcoma.
  • [MeSH-major] Sarcoma / drug therapy
  • [MeSH-minor] Chordoma / drug therapy. Cyclin-Dependent Kinase 4 / genetics. Drug Discovery. Humans. Liposarcoma / drug therapy. Liposarcoma / genetics. Neovascularization, Pathologic / drug therapy. Proteomics. Proto-Oncogene Proteins c-mdm2 / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Semin Oncol. 2009 Oct;36(5):489. Maestro, Roberta [added]
  • (PMID = 19664496.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Number-of-references] 83
  •  go-up   go-down


76. Goss G, Demetri G: Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care. Surg Oncol; 2000 Aug;9(2):53-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care.
  • Liposarcomas of the retroperitoneum are rare tumors, and best managed by an expert multidisciplinary team consisting of a surgical oncologist with appropriate medical oncology and radiation oncology collaboration.
  • For large tumors, surgical excision with wide margins is difficult to achieve, and even wide margins cannot ensure that microscopic remnants of residual disease will not grow back in the future.
  • For patients with recurrent and unresectable liposarcoma, treating the sarcoma while maintaining quality of life becomes the major therapeutic goal.
  • Importantly, patients with advanced recurrent disease demonstrate the need for multidisciplinary team involvement, with timely consideration of palliative surgical, radiation therapy, and chemotherapy options.
  • Such patients also represent ideal candidates for investigational approaches aimed at identifying new agents with which to treat this disease.
  • In addition to the development of new cytotoxic agents, patients may be candidates for novel strategies such as differentiation therapies or anti-angiogenic approaches.
  • The recent explosion of knowledge regarding the cytogenetics, molecular, and cellular biology of liposarcomas allows us to remain positive that new translational therapies will be developed to improve the clinical outcomes of patients with these diseases.
  • Current strategies, such as the use of PPARgamma ligands to differentiate liposarcomas, will soon be tested in major national collaborative trials, and the cooperation of surgeons and medical oncologists at all levels of community and academic practice will be crucial to obtain answers in this field.
  • This review will summarize an illustrative case in the process of describing the natural history and potential interventions which should be considered for patients with this disease.
  • [MeSH-major] Chromans / administration & dosage. Liposarcoma / drug therapy. Liposarcoma / surgery. Neoplasm Recurrence, Local / drug therapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / surgery. Thiazoles / administration & dosage. Thiazolidinediones
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094323.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Chromans; 0 / Thiazoles; 0 / Thiazolidinediones; I66ZZ0ZN0E / troglitazone
  • [Number-of-references] 26
  •  go-up   go-down


77. Vallurupalli S, Huesmann G, Gregory J, Jakoby MG 4th: Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med; 2008 Jul;25(7):856-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 63-year-old man with Type 2 diabetes mellitus was admitted to hospital for resection of a large liposarcoma.
  • On days 6-8 of levofloxacin therapy, the patient experienced recurrent hypoglycaemia despite total parenteral nutrition, 10% dextrose containing fluids and cessation of insulin therapy 3 days prior to the first hypoglycaemic episode.
  • After a final and severe hypoglycaemic event, the patient developed quadriplegia and tonic left deviation of gaze.
  • [MeSH-minor] Diabetes Mellitus, Type 2 / complications. Diabetic Neuropathies / complications. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / surgery. Liposarcoma / complications. Liposarcoma / surgery. Male. Middle Aged. Myelinolysis, Central Pontine / complications. Peritonitis / prevention & control. Postoperative Complications / prevention & control

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Hypoglycemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Levofloxacin .
  • Hazardous Substances Data Bank. Ofloxacin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2007 Apr;117(4):910-8 [17404617.001]
  • [Cites] Intensive Care Med. 2000 Sep;26(9):1406-7 [11089780.001]
  • [Cites] Diabetes Care. 1984 Nov-Dec;7(6):613 [6391878.001]
  • [Cites] Stroke. 1992 Jan;23(1):112-3 [1731410.001]
  • [Cites] Stroke. 1993 Jan;24(1):143 [8418544.001]
  • [Cites] Brain Res. 1993 Mar 19;606(1):19-27 [8096428.001]
  • [Cites] Stroke. 1996 Sep;27(9):1648-55; discussion 1655-6 [8784143.001]
  • [Cites] Drug Saf. 1998 Feb;18(2):83-97 [9512916.001]
  • [Cites] N Engl J Med. 2006 Mar 30;354(13):1352-61 [16510739.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jan;65(1):1-11 [16410743.001]
  • [Cites] Neuroreport. 2006 Jan 23;17(1):55-9 [16361950.001]
  • [Cites] Pharmacotherapy. 2005 Oct;25(10):1303-9 [16185173.001]
  • [Cites] Pharmacotherapy. 2005 Oct;25(10):1296-302 [16185172.001]
  • [Cites] Gen Hosp Psychiatry. 2005 Sep-Oct;27(5):372-4 [16168799.001]
  • [Cites] Stroke. 2005 Mar;36(3):e20-2 [15692119.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1959 Feb;81(2):154-72 [13616772.001]
  • [Cites] Diabet Med. 1998 Mar;15(3):259-61 [9545129.001]
  • [Cites] Diabet Med. 2004 Jun;21(6):623-4 [15154950.001]
  • [Cites] Eur J Pharmacol. 2004 Aug 16;497(1):111-7 [15321742.001]
  • (PMID = 18644072.001).
  • [ISSN] 1464-5491
  • [Journal-full-title] Diabetic medicine : a journal of the British Diabetic Association
  • [ISO-abbreviation] Diabet. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 6GNT3Y5LMF / Levofloxacin; A4P49JAZ9H / Ofloxacin
  • [Other-IDs] NLM/ PMC2613252
  •  go-up   go-down


78. Minematsu N, Minato N, Kamohara K, Hakuba T: Complete removal of heart-compressing large mediastinal lipoma: a case report. J Cardiothorac Surg; 2010;5:48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although preoperative examination could not determine whether the tumor was lipoma or liposarcoma, we selected an invasive surgical therapy because neither radiation therapy nor chemotherapy was considered effective for either type of tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2000 May;69(5):1579-80; discussion 1581 [10881849.001]
  • [Cites] Radiographics. 2002 Oct;22 Spec No:S61-78 [12376601.001]
  • [Cites] Ann Thorac Surg. 2005 Oct;80(4):e10-2 [16181831.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:367-88 [13890373.001]
  • [Cites] J Thorac Cardiovasc Surg. 1977 Jul;74(1):83-97 [875445.001]
  • (PMID = 20525269.001).
  • [ISSN] 1749-8090
  • [Journal-full-title] Journal of cardiothoracic surgery
  • [ISO-abbreviation] J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2892490
  •  go-up   go-down


79. Fernández-Veledo S, Nieto-Vazquez I, de Castro J, Ramos MP, Brüderlein S, Möller P, Lorenzo M: Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytes. J Clin Endocrinol Metab; 2008 Jul;93(7):2866-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Adipocytes release a variety of factors which deregulation could provide the basis for complications such as insulin resistance, an early defect on the onset of type 2 diabetes.
  • OBJECTIVE: The objective of the study was to dissect the molecular mechanisms that may regulate hyperinsulinemia-induced insulin resistance in a human liposarcoma cell line and its paracrine interactions with a human rhabdomyosarcoma cell line.
  • Pharmacological treatment of adipocytes with a liver X receptor agonist reestablishes insulin-stimulated glucose uptake, whereas treatment with a peroxisome proliferator-activated receptor-gamma agonist restored the antilipolytic action of insulin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18430774.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / DNA-Binding Proteins; 0 / Fatty Acids, Nonesterified; 0 / Hydrocarbons, Fluorinated; 0 / Interleukin-6; 0 / Orphan Nuclear Receptors; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Sulfonamides; 0 / TO-901317; 0 / liver X receptor; IY9XDZ35W2 / Glucose
  •  go-up   go-down


80. Nezame FS, Krarup-Hansen A, Bergenfeldt M: [Retroperitoneal sarcomas - size not decisive]. Ugeskr Laeger; 2008 Feb 18;170(8):655
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Retroperitonealt liposarkom - størrelsen er ikke afgørende.
  • A 70 year-old female presented with a 40 x 40 cm unresectable liposarcoma which showed progression during chemotherapy.
  • The second case concerns a 64 year-old male with a 19 x 15 cm liposarcoma in the upper abdomen.
  • Both patients recovered without complications, and remain disease-free at two years.
  • Retroperitoneal sarcomas are notoriously "silent", and may grow to considerable size before diagnosis.
  • [MeSH-major] Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364162.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


81. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, Gronchi A, Pilotti S, Casali PG: Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol; 2009 Aug;20(8):1439-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series.
  • BACKGROUND: Trabectedin has been approved in Europe as second-line therapy for advanced soft tissue sarcomas.
  • A previous analysis showed that myxoid liposarcomas (MLS) are particularly sensitive to the drug.
  • In 10 patients, therapy was stopped in the absence of any evident disease, mostly after complete surgery of residual lesions.
  • In these 10 patients, at a median follow-up of 25 months, PFS was 28.1 months (95% CI 25.6-36.4) from treatment start.
  • Surgery of residual metastatic disease is already used quite extensively in metastatic MLS.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19465423.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Dioxoles; 0 / Tetrahydroisoquinolines; 114899-77-3 / trabectedin
  •  go-up   go-down


82. Kulke MH, Demetri GD, Sharpless NE, Ryan DP, Shivdasani R, Clark JS, Spiegelman BM, Kim H, Mayer RJ, Fuchs CS: A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J; 2002 Sep-Oct;8(5):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer.
  • PURPOSE: Troglitazone, a potent activator of the peroxisome proliferator-activated receptor-gamma, induces tumor differentiation in human liposarcomas and causes regression of tumors that are derived from human colon cancer cells in nude mice.
  • We therefore assessed the efficacy of troglitazone in the treatment of metastatic colon cancer in humans.
  • RESULTS: The treatment was well tolerated: no grade 3/4 treatment-related toxicities were observed.
  • However, no objective tumor responses were noted, and all 25 patients had progressive disease as their best response to therapy.
  • The median progression-free survival time was only 1.6 months, and the median survival time was 3.9 months.
  • DISCUSSION: Troglitazone is not an active agent for the treatment of metastatic colorectal cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Chromans / therapeutic use. Colorectal Neoplasms / drug therapy. Receptors, Cytoplasmic and Nuclear / agonists. Thiazoles / therapeutic use. Thiazolidinediones. Transcription Factors / agonists
  • [MeSH-minor] Adult. Aged. Disease Progression. Drug Resistance, Neoplasm. Female. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Survival Analysis. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12416897.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 0 / Transcription Factors; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


83. Della Vittoria Scarpati M, Della Vittoria Scarpati G, Santini M, Vicidomini G, Parascandolo V: [Retroperitoneal pleomorphic liposarcoma. A case of survival after ten years]. Recenti Prog Med; 2004 Jan;95(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retroperitoneal pleomorphic liposarcoma. A case of survival after ten years].
  • [Transliterated title] Liposarcoma pleomorfo retroperitoneale. Dieci anni di sopravvivenza.
  • Sarcomas are malignant neoplasms which can involve both soft tissues and/or bones.
  • The soft tissues sarcomas are very rare, representing about 1% of all malignant tumors.
  • Currently, surgery is the only curative therapy for soft tissues sarcomas in adult patients, with the exclusion of retroperitoneal sarcomas, which have have poor prognosis, due to look of surgical radicality and low radiotherapy and chemotherapy responsiveness.
  • In fact, chemotherapy by conventional regimens, as adriamicine plus ifosfamide or CYVADIC, allows not more than 25% of partial responses, with a median survival of 12 months.
  • [MeSH-major] Liposarcoma / therapy. Retroperitoneal Neoplasms / therapy
  • [MeSH-minor] Aged. Humans. Male. Survivors. Time Factors

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15032338.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


84. Gritli S, Khamassi K, Lachkhem A, Touati S, Chorfa A, Ben Makhlouf T, El May A, Gammoudi A: Head and neck liposarcomas: a 32 years experience. Auris Nasus Larynx; 2010 Jun;37(3):347-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Head and neck liposarcomas: a 32 years experience.
  • OBJECTIVE: The aim of this review is to study natural history, presentation, treatment and prognosis of head and neck liposarcomas.
  • Therapeutic modalities included surgery, radiotherapy and chemotherapy.
  • Histological types of liposarcomas were the following: myxoid (5 cases), well differentiated (4 cases), pleomorphic (4 cases), round cell (1 case) and dedifferentiated (1 case).
  • After initial treatment, complete remission was achieved in 7 cases (46.7%).
  • Two of these patients were reoperated and another one received chemotherapy.
  • In the other 5 cases, the tumor was uncontrollable and no additional treatment has been proposed.
  • CONCLUSION: The mainstay of treatment of head and neck liposarcomas is surgical excision and the prognosis is largely determined by the histological grade and the clinical stage.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy. Liposarcoma / pathology. Liposarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Middle Aged. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19857936.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


85. Neragi-Miandoab S, Kim J, Vlahakes GJ: Malignant tumours of the heart: a review of tumour type, diagnosis and therapy. Clin Oncol (R Coll Radiol); 2007 Dec;19(10):748-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumours of the heart: a review of tumour type, diagnosis and therapy.
  • Primary cardiac neoplasms are rare and occur less commonly than metastatic disease of the heart.
  • In this overview, current published studies concerning malignant neoplasms of the heart are reviewed, together with some insights into their aetiology, diagnosis and management.
  • Sarcomas are the most common cardiac tumours and include myxosarcoma, liposarcoma, angiosarcoma, fibrosarcoma, leiomyosarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma, neurofibrosarcoma, malignant fibrous histiocytoma and undifferentiated sarcoma.
  • However, serious complications including stroke, myocardial infarction and even sudden death from arrhythmia may be the first signs of a tumour.
  • Computed tomography and magnetic resonance imaging studies have improved the diagnostic approach in recent decades.
  • Successful treatment for benign cardiac tumours is usually achieved by surgical resection.
  • The prognosis after surgery is usually excellent in the case of benign tumours, but the prognosis of malignant tumours remains dismal.
  • Therefore, a high level of suspicion is required for early diagnosis.
  • Surgery is the cornerstone of therapy.
  • However, a multi-treatment approach, including chemotherapy, radiation as well as evolving approaches such as gene therapy, might provide a better palliative and curative result.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Cardiovascular Surgical Procedures. Echocardiography, Three-Dimensional. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17693068.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 77
  •  go-up   go-down


86. Maki RG: Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist; 2007 Aug;12(8):999-1006
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Objective. In the era of oral molecular kinase inhibitors, cytotoxic chemotherapy agents are somewhat overlooked, but remain the backbone of treatment for most cancers.
  • Patients with non-gastrointestinal stromal tumor sarcomas, such as leiomyosarcoma, liposarcoma, and undifferentiated high-grade pleomorphic sarcoma (formerly called malignant fibrous histiocytoma), have received doxorubicin and ifosfamide as the backbone of their treatment for over 15 years or more.
  • Conclusions. The combination of gemcitabine and docetaxel is an effective option for patients with metastatic sarcoma, increasing the armamentarium for the practicing oncologist in treating this heterogeneous group of diseases.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Deoxycytidine / analogs & derivatives. Sarcoma / drug therapy. Sarcoma / pathology. Taxoids / therapeutic use
  • [MeSH-minor] Drug Synergism. Humans


87. Roche M, Tarnus E, Rondeau P, Bourdon E: Effects of nutritional antioxidants on AAPH- or AGEs-induced oxidative stress in human SW872 liposarcoma cells. Cell Biol Toxicol; 2009 Dec;25(6):635-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of nutritional antioxidants on AAPH- or AGEs-induced oxidative stress in human SW872 liposarcoma cells.
  • High levels of oxidative stress were reported in obesity-linked type 2 diabetes and were associated with elevated formation of advanced glycation end products (AGEs).
  • Caffeic acid, quercetin, L: -ascorbic acid, and alpha-tocopherol were tested on SW872 liposarcoma cells subjected to a free radical generator or to AGEs.
  • Our findings clearly show a novel antioxidant role for caffeic acid and quercetin at the adipose tissue level.
  • [MeSH-major] Adipocytes / drug effects. Adipocytes / metabolism. Antioxidants / pharmacology. Ascorbic Acid / pharmacology. Ascorbic Acid / therapeutic use. Caffeic Acids / pharmacology. Cell Proliferation / drug effects. Cell Survival / drug effects. Quercetin / pharmacology. Superoxide Dismutase / metabolism. Tocopherols / pharmacology
  • [MeSH-minor] Amidines / metabolism. Amidines / pharmacology. Animals. Cattle. Cell Line. Diabetes Mellitus, Type 2 / drug therapy. Diabetes Mellitus, Type 2 / etiology. Free Radicals / metabolism. Glycosylation End Products, Advanced / metabolism. Glycosylation End Products, Advanced / pharmacology. Humans. Obesity / complications. Oxidants / metabolism. Oxidants / pharmacology. Oxidative Stress / drug effects. Phytotherapy. Serum Albumin, Bovine / metabolism. Serum Albumin, Bovine / pharmacology. Up-Regulation / drug effects

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. QUERCETIN .
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. CAFFEIC ACID .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19152116.001).
  • [ISSN] 1573-6822
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Amidines; 0 / Antioxidants; 0 / Caffeic Acids; 0 / Free Radicals; 0 / Glycosylation End Products, Advanced; 0 / Oxidants; 0 / Serum Albumin, Bovine; 0 / advanced glycation end products-bovine serum albumin; 13217-66-8 / 2,2'-azobis(2-amidinopropane); 1406-66-2 / Tocopherols; 9IKM0I5T1E / Quercetin; EC 1.15.1.1 / Superoxide Dismutase; PQ6CK8PD0R / Ascorbic Acid; U2S3A33KVM / caffeic acid
  •  go-up   go-down


88. Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK: Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther; 2008 Apr;7(4):890-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
  • Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue tumors with a very poor prognosis and largely resistant to chemotherapy.
  • MPNSTs are characterized by activation of the Ras pathway by loss of tumor suppressor neurofibromatosis type 1.
  • MPNST (MPNST and ST8814) and dedifferentiated liposarcoma (LS141 and DDLS) human tumor cell lines were characterized for Ras activation and B-Raf expression.
  • These effects were not seen in the liposarcoma cells, which either did not express B-Raf or showed decreased Ras activation.
  • Small interfering RNA-mediated depletion of B-Raf in MPNSTs also induced a G(1) cell cycle arrest in these cells, with a marked inhibition of cyclin D1 expression and Rb phosphorylation, whereas depletion of C-Raf did not affect either.
  • With growth inhibition at the low nanomolar range, sorafenib, by inhibiting the mitogen-activated protein kinase pathway, may prove to be a novel therapy for patients with MPNST.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1999 Dec;155(6):1885-91 [10595919.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1070-8 [17363500.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Curr Pharm Des. 2002;8(25):2255-7 [12369853.001]
  • [Cites] Leukemia. 2003 Jul;17(7):1263-93 [12835716.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):95-8 [12957284.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5198-202 [14500344.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3763-71 [15173083.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):7099-109 [15466206.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] Cell. 1992 Apr 17;69(2):265-73 [1568246.001]
  • [Cites] Nature. 1992 Apr 23;356(6371):713-5 [1570015.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20608-16 [8702807.001]
  • [Cites] Development. 1998 Dec;125(24):4999-5008 [9811584.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Sep;54 Suppl 1:S69-77 [15316751.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):677-85 [15827342.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):358-62 [16273091.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9238-50 [16452469.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5533-42 [17000690.001]
  • [Cites] Trends Mol Med. 2002 Jan;8(1):17-23 [11796262.001]
  • (PMID = 18413802.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA047179-16; United States / NCI NIH HHS / CA / T32 CA009501-18; United States / NCI NIH HHS / CA / T32 CA009501; United States / NCI NIH HHS / CA / T32 CA009501-17; United States / NCI NIH HHS / CA / P01 CA047179-17; United States / NCI NIH HHS / CA / CA09501; United States / NCI NIH HHS / CA / P01 CA047179
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS349129; NLM/ PMC3267321
  •  go-up   go-down


89. Dass CR, Galloway SJ, Clark JC, Khachigian LM, Choong PF: Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy. Cancer Biol Ther; 2008 Aug;7(8):1297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy.
  • Recently, this oncogene has also been implicated in liposarcoma (LS) progression. c-jun knockdown mediated by a deoxyribozyme induced apoptosis in LS cells via evoking caspase-10, but not the Fas/FasL pathway.
  • Clinically, downregulation of c-jun may proffer an improved treatment outcome for liposarcoma.
  • The new model for LS described here will enable better testing of agents with therapeutic potential against LS.
  • [MeSH-major] Liposarcoma / pathology. Proto-Oncogene Proteins c-jun / metabolism
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Caspase 10 / metabolism. Cell Line, Tumor. DNA, Catalytic / metabolism. DNA, Catalytic / pharmacology. Disease Models, Animal. Humans. Immunohistochemistry. Male. Mice. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2008 Aug;7(8):1302-4 [18708756.001]
  • (PMID = 18497564.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Catalytic; 0 / Proto-Oncogene Proteins c-jun; EC 3.4.22.- / Caspase 10
  •  go-up   go-down


90. Farina GP, Baccoli A, Pani C, Cagetti M: [Retroperitoneal sarcomas: our experience]. G Chir; 2004 May;25(5):163-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Retroperitoneal soft tissues sarcomas (STS) are relatively uncommon and constitute a difficult management problem.
  • Although surgical resection is often difficult or impossible, current chemotherapy is not effective and radiation is limited by toxicity to adjacent structures.
  • Thus, complete surgical resection remains the most effective modality for selected primary and recurrent disease.
  • Nine patients underwent complete surgical resection of 8 malignant and 1 benign tumor.
  • Two patients underwent incomplete surgical resection of 1 malignant and 1 benign tumor.
  • Patient, tumor, and treatment variables were analyzed for disease-specific and disease-free survival.
  • RESULTS: The patients with unresectable disease, incomplete resection, and high-grade tumors presented significantly reduced survival time.
  • Because death often occurs as a result of local progression in retroperitoneal liposarcomas, it is possible that incomplete resection may be beneficial in this histologic type.
  • Complete surgical resection is the most effective modality for the treatment of retroperitoneal sarcomas.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15382473.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Orditura M, Lieto E, Ferraraccio F, De Cataldis G, Troiani T, Castellano P, Catalano G, Ciardiello F, Galizia G, De Vita F: Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass. World J Surg Oncol; 2007;5:42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass.
  • BACKGROUND: Hepatoid adenocarcinoma (HAC) is a peculiar type of extrahepatic adenocarcinoma generally characterized by adenocarcinomatous and hepatocellular carcinoma (HCC)-like foci.
  • On the other side, liposarcoma is a rare, malignant tumor that develops from fat cells.
  • CASE PRESENTATION: We describe here a case of hepatoid carcinoma in collision with a liposarcoma of the left colon serosa in a 71-year-old man.
  • The patient had an objective response following liposomal antracycline chemotherapy, with a 3-year overall survival.
  • CONCLUSION: To our knowledge, this is the first case of a hepatoid tumor colliding with a liposarcoma of the left colon serosa reported to date.
  • [MeSH-major] Abdominal Neoplasms / pathology. Adenocarcinoma / pathology. Carcinoma, Hepatocellular / pathology. Colonic Neoplasms / pathology. Liposarcoma / pathology. Neoplasms, Multiple Primary / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1999 Jul;35(1):90-2 [10383723.001]
  • [Cites] J Clin Pathol. 1996 May;49(5):420-2 [8707961.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1919-25 [7511041.001]
  • [Cites] Acta Pathol Jpn. 1993 Nov;43(11):654-61 [7508672.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1827-35 [7689918.001]
  • [Cites] Int J Gynecol Pathol. 1991;10(3):302-10 [1717389.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1113-8 [9298890.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(1):73-80 [1694332.001]
  • [Cites] Cancer. 1987 Dec 1;60(11):2775-84 [2445465.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1582-9 [10738216.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):226-30 [10982619.001]
  • [Cites] Med Electron Microsc. 2000;33(2):57-63 [11810459.001]
  • [Cites] Cancer. 1991 Jun 15;67(12):3051-6 [1710536.001]
  • (PMID = 17448253.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1866233
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


92. Chughtai A, Cronin P, Lucas DR, Prager R, Kazerooni EA: Metastatic shoulder liposarcoma to the right ventricle: CT findings. J Thorac Imaging; 2007 May;22(2):195-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic shoulder liposarcoma to the right ventricle: CT findings.
  • Metastatic cardiac liposarcoma is rare.
  • A right ventricular liposarcoma metastasis is described in a 46-year-old man, who was admitted with significant shortness of breath and fatigue, and in whom a large lobulated low attenuation mass occupying most of the right ventricular cavity, with extension through the right ventricular apex and a small-to-moderate pericardial effusion was detected by electrocardiogram-gated cardiac computed tomography.
  • The patient had an antecedent history of a left upper arm liposarcoma treated with surgical resection, chemotherapy, and postoperative radiotherapy 3 years earlier.
  • The histopathologic analysis revealed a liposarcoma, similar to the one resected in the left arm 3 years earlier.
  • Electrocardiogram-gated cardiac computed tomography was able to visualize the metastatic tumor within the heart, accurately evaluate cardiac function and allow for prompt surgical treatment that produced relief of symptoms, and assess for further metastatic disease within the thorax.
  • [MeSH-major] Bone Neoplasms / pathology. Heart Neoplasms / diagnosis. Heart Neoplasms / secondary. Liposarcoma / diagnosis. Shoulder / pathology. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media / administration & dosage. Dyspnea / etiology. Electrocardiography / methods. Fatigue / etiology. Heart Ventricles / radiography. Heart Ventricles / surgery. Humans. Iohexol. Male. Middle Aged. Radiographic Image Enhancement / methods. Rare Diseases

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527130.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


93. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D: Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One; 2010;5(4):e9747
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.
  • BACKGROUND: Diagnosis of soft tissue sarcomas (STS) is challenging.
  • Many remain unclassified (not-otherwise-specified, NOS) or grouped in controversial categories such as malignant fibrous histiocytoma (MFH), with unclear therapeutic value.
  • We analyzed several independent microarray datasets, to identify a predictor, use it to classify unclassifiable sarcomas, and assess oncogenic pathway activation and chemotherapy response.
  • We developed and validated a predictor, which was used to reclassify MFH and NOS sarcomas.
  • Bayesian models of oncogenic pathway activation and chemotherapy response were applied to individual STS samples.
  • A 170-gene predictor was developed and independently validated (80-85% accuracy in all datasets).
  • Most MFH and NOS tumors were reclassified as leiomyosarcomas, liposarcomas and fibrosarcomas.
  • This classification revealed previously unrecognized tissue differentiation lines (adipocyte, fibroblastic, smooth-muscle) and was reproduced in paraffin specimens.
  • CONCLUSIONS/SIGNIFICANCE: STS profiling can aid in diagnosis through a predictor tracking distinct tissue differentiation in unclassified tumors, and in therapeutic management via oncogenic pathway activation and chemotherapy response assessment.
  • [MeSH-major] Bayes Theorem. Neural Networks (Computer). Oligonucleotide Array Sequence Analysis. Sarcoma / classification. Sarcoma / genetics
  • [MeSH-minor] Cluster Analysis. Databases, Nucleic Acid. Drug Resistance, Neoplasm / genetics. Expert Systems. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Soft Tissue Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):77-80 [11250749.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Curr Oncol Rep. 2001 May;3(3):243-9 [11296135.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):330-9 [18286476.001]
  • [Cites] Methods Mol Biol. 2008;439:159-77 [18370102.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Expert Opin Ther Targets. 2008 May;12(5):589-603 [18410242.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):543-8 [14962721.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1799-807 [15509548.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:318-26 [9474886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5881-9 [15994966.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6280-90 [16144932.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7332-41 [16145063.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Biostatistics. 2007 Jan;8(1):118-27 [16632515.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):517-25 [17290060.001]
  • [Cites] Clin Transl Oncol. 2007 Mar;9(3):130-44 [17403624.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] PLoS One. 2007;2(10):e1002 [17912341.001]
  • [Cites] PLoS One. 2007;2(11):e1195 [18030330.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):346-51 [18199526.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):1-9 [18187804.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • (PMID = 20368975.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2848563
  •  go-up   go-down


94. Carrión López P, Pastor Navarro H, Martínez Ruiz J, Giménez Bachs JM, Donate Moreno MJ, Polo Ruiz L, Pastor Guzmán JM, Martínez Sanchiz C, Ruiz Mondéjar R, Virseda Rodríguez JA: [Spermatic cord sarcomas: current status and report of four cases]. Arch Esp Urol; 2009 Apr;62(3):242-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Sarcomas de cordón espermático: estado actual y presentación de cuatro casos clínicos.
  • OBJECTIVE: To study and review spermatic cord sarcomas, including symptoms, diagnosis, and treatment.
  • METHODS/RESULTS: We review the Spanish and international literature and report 4 new cases: 2 patients with well-differentiated spermatic cord liposarcomas (1 treated by simple tumorectomy), 1 patient with liposarcomatous degeneration of a previously excised atypical lipoma, and 1 patient operated for a malignant retroperitoneal fibrous histiocytoma with subsequent local recurrence in the paratesticular region.
  • They are diagnosed by imaging studies (ultrasound, computed tomography, magnetic resonance) and confirmed by histological examination.
  • Spermatic cord sarcomas are treated surgically; the efficacy of adjuvant treatments such as chemotherapy or radiation therapy is still under debate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554782.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 12
  •  go-up   go-down


95. Berry MF, Sporn TA, Moore JO, D'Amico TA: Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection. J Thorac Oncol; 2009 Jun;4(6):768-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Liposarcoma / surgery. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Doxorubicin / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19461403.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


96. Schofer MD, Abu-Safieh MY, Paletta J, Fuchs-Winkelmann S, El-Zayat BF: Liposarcoma of the forearm in a man with type 1 neurofibromatosis: a case report. J Med Case Rep; 2009;3:7071
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the forearm in a man with type 1 neurofibromatosis: a case report.
  • INTRODUCTION: The combination of neurofibromatosis and liposarcoma is very rare.
  • We present a case of a dedifferentiated liposarcoma in the forearm, as a complication in a patient with neurofibromatosis type 1.
  • CASE PRESENTATION: A Caucasian man with neurofibromatosis type 1 presented at our clinic complaining of a slow growing swelling on his left forearm over a period of one and a half years.
  • Radiological examination inclusive of magnetic resonance imaging and positron emission tomography confirmed our suspicion.
  • A final diagnosis of dedifferentiated high-grade liposarcoma with axillary lymph node metastases was established after a pathological examination of a tumour biopsy.
  • The treatment was completed with postoperative radiotherapy of the left forearm's operative bed, the left axillary and the supraclavicular regions.
  • The patient decided against adjuvant chemotherapy.
  • CONCLUSION: Liposarcoma complicating neurofibromatosis type 1 is a very rare combination.
  • It is the first known case with this disease combination in an upper extremity.
  • Liposarcoma is usually treated by surgery followed by radiotherapy.
  • The role of chemotherapy is controversial and should be based on a decision made on a case-by-case basis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sarcoma. 2008;2008:459386 [18497869.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1238-47 [11230464.001]
  • [Cites] J Obstet Gynaecol. 2006 May;26(4):381-2 [16753705.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] Cancer. 1963 Aug;16:1015-27 [14050005.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):540-6 [9344320.001]
  • [Cites] Am J Surg Pathol. 1997 Mar;21(3):271-81 [9060596.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Neurofibromatosis. 1989;2(1):6-22 [2517025.001]
  • [Cites] Bull Hosp Jt Dis Orthop Inst. 1982 Fall;42(2):172-86 [6309294.001]
  • [Cites] Skeletal Radiol. 1981;7(2):150-3 [6800037.001]
  • [Cites] Plast Reconstr Surg. 1978 Feb;61(2):287-90 [414243.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):298-313 [18286473.001]
  • (PMID = 19830134.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2726491
  •  go-up   go-down


97. Malizia M, Brunocilla E, Bertaccini A, Palmieri F, Vitullo G, Martorana G: Liposarcoma of the spermatic-cord: description of two clinical cases and review of the literature. Arch Ital Urol Androl; 2005 Jun;77(2):115-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the spermatic-cord: description of two clinical cases and review of the literature.
  • Spermatic cord liposarcoma is a rare tumor; currently only 161 cases are described in literature.
  • Radical surgery represents the therapy of choice whilst uncertain is the role of regional and retroperitoneal lymphadenectomy as well as the usefulness of adjuvant radiotherapy or chemotherapy.

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146276.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 16
  •  go-up   go-down


98. Pradat PF, Attarian S, Camdessanché JP, Carluer L, Cintas P, Corcia P, Echaniz-Laguna A, Gonzalez-Bermejo J, Guy N, Nicolas G, Perez T, Soriani MH, Vandenberghe N, Verschueren A, coordination des centres de prise en charge des patients atteints de SLA: [Research in amyotrophic lateral sclerosis: what is new in 2009?]. Rev Neurol (Paris); 2010 Aug-Sep;166(8-9):683-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La recherche sur la SLA en 2009 : compte rendu du groupe bibliographique de la coordination des centres SLA.
  • In the field of genetics, research has been advanced through the identification of mutations of the gene FUsed in Sarcoma/Translated in LipoSarcoma (FUS/TLS) in individuals with familial and sporadic ALS.
  • A report showed that mice expressing a mutant form of human TDP-43 develop a progressive and fatal neurodegenerative disease reminiscent of both ALS and frontotemporal lobar degeneration with ubiquitin aggregates (FTLD-U), providing a new animal model that may help to better understand the pathophysiology and test new therapeutics.
  • Therapeutic trials have been performed or are currently ongoing in Europe and North America.
  • [MeSH-minor] Animals. Biomarkers. Clinical Trials as Topic. DNA-Binding Proteins / deficiency. DNA-Binding Proteins / genetics. DNA-Binding Proteins / physiology. Disease Models, Animal. Drug Evaluation, Preclinical. Environmental Exposure. Humans. Malnutrition / etiology. Malnutrition / therapy. Mice. Mice, Transgenic. Muscle, Skeletal / metabolism. Neuroprotective Agents / therapeutic use. RNA-Binding Protein FUS / deficiency. RNA-Binding Protein FUS / genetics. RNA-Binding Protein FUS / physiology. Risk Factors. Superoxide Dismutase / deficiency. Superoxide Dismutase / genetics. Superoxide Dismutase / physiology

  • Genetic Alliance. consumer health - Amyotrophic Lateral Sclerosis.
  • MedlinePlus Health Information. consumer health - Amyotrophic Lateral Sclerosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20472259.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers; 0 / DNA-Binding Proteins; 0 / Neuroprotective Agents; 0 / RNA-Binding Protein FUS; EC 1.15.1.- / superoxide dismutase 1; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


99. Yoshida Y, Inoue K, Ohsako T, Nagamoto N, Tanaka E, Tsuruzoe S: [Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma]. Gan To Kagaku Ryoho; 2007 Mar;34(3):465-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Weekly paclitaxel therapy is curative for patients with retroperitoneal liposarcoma].
  • In March 2004, we resected a giant retroperitoneal liposarcoma and the transverse colon, spleen and left kidney in a 58-year-old woman.
  • In September 2004, computed tomography (CT) revealed multiple recurrences in the right lower abdomen, left upper abdomen, front of the left lobe of the liver, and at the back of the stomach.
  • In October 2004, we started mesna, doxorubicin, ifosfamide, and dacarbazine therapy (MAID); however, after 1 course, the disease progressed, and the patient developed edema in the bilateral legs due to inferior vena cava (IVC) compression.
  • In November 2004, we started weekly paclitaxel therapy (100 mg/m(2), once a week for 3 weeks followed by 1 drug-free week).
  • CT revealed no change as a result of chemotherapy; however, IVC compression had improved, and leg edema had decreased.
  • In August 2005, chemotherapy was stopped; therefore,the patient's condition worsened.
  • We performed weekly paclitaxel therapy for the patient with recurrent liposarcoma.
  • Therefore,we consider weekly paclitaxel therapy to be effective for liposarcoma treatment.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Liposarcoma / drug therapy. Paclitaxel / therapeutic use. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Colectomy. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Middle Aged. Nephrectomy. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / secondary. Quality of Life. Spleen / surgery

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17353645.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


100. Stoeckle E, Coindre JM, Bonvalot S, Kantor G, Terrier P, Bonichon F, Nguyen Bui B, French Federation of Cancer Centers Sarcoma Group: Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer; 2001 Jul 15;92(2):359-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group.
  • However, despite progress, surgery alone is rarely curative, and analysis of the causes of failures and of other prognostic factors are warranted to ascertain treatment orientations.
  • Liposarcoma, leiomyosarcoma, and malignant fibrous histiocytoma represented 66% of the tumors.
  • Multimodality treatment included surgery (150 patients), radiotherapy (92 patients), and chemotherapy (77 patients).
  • The main prognostic factors for survival were initial metastases and surgery, which represented the major treatment-linked factor.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11466691.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down






Advertisement